Natural occurring regulatory T cells: role of transcription factor FOXP3 and new approaches improving Treg-cell based therapy by Fanelli, Giorgia
                                                                 
 
Natural occurring regulatory T cells: role of transcription 
factor FOXP3 and new approaches improving  
Treg-cell based therapy 
  
                                                            
 
By Giorgia Fanelli 
 
 
 
Department of Biology and Biotechnology  
 “Charles Darwin” “Sapienza”, University of Rome 
                                   
 
 
 
XXV cycle 
2012 
                                                                                 
 2 
Scientific Tutors: 
Prof. Enza Piccolella        
Department of Biology and Biotechnology “Charles Darwin” 
Sapienza, University of Rome 
 
 
Prof. Rodolfo Negri  
Department of Biology and Biotechnology “Charles Darwin” 
Sapienza, University of Rome 
 
 
Prof. Giovanna Lombardi 
Department of “Transplantation Immunology & Mucosal Biology” 
King’s College, London 
      
 
 
 
 
Board of examiners: 
Prof. Carlo Cogoni 
Department of Cellular Biotechnologies and Hematology,  
Sapienza, University of Rome 
 
 
Prof. Michela Ori 
Department of Cellular and Developmental Biology, 
University of Pisa 
 
 
Dott.ssa. Maria Cristina Gagliardi 
Department of Infectious Diseases Parasitic and Immunomediated, 
ISS, Rome 
 3 
 
Prologue 
        Research carried out over the past 10-20 years, has greatly expanded our understanding 
of how T-cell subsets differentiate and acquire a degree of stability that allows them to be 
considered a distinct T-cell lineage. This is the case for CD4+ regulatory T cells (Treg cells), a 
class of T cells that develops in the thymus and is essential for maintaining self-tolerance.  
Treg cells are characterized by the expression of the transcription factor forkhead box P3 
(FOXP3), which is essential for the normal development and function of these cells. Although 
several subsets of T cells with immunosuppressive properties have been identified, FOXP3+ 
Treg cells have emerged as a dominant cell type. The first indication that cells with regulatory 
characteristics could exist and be important for self-tolerance came from work by Nishizuka 
and Sakakara in 1969 in which they observed that neonatal thymectomy of mice 2-4 days 
after birth resulted in autoimmunity. This autoimmunity could be transferred to 
immunodeficient mice by adoptive transfer of T cells, and the autoimmunity could be 
reversed in thymectomized mice by transfer of T cells from wild type mice. Gershon and 
Kondo formally proposed the existence of “T suppressor” cells in 1970 after observing that T 
cells could suppress antibody responses. It wasn’t until after 1995, however, that intense 
research into T cells with regulatory properties began, following the discovery by Shimon 
Sakaguchi that T cells with regulatory capacity highly express the IL-2 receptor alpha chain 
(CD25), providing a means by which to enrich for and study these cells. Sakaguchi observed 
that transfer of CD4+CD25- T cells into immunodeficient mice resulted in autoimmunity 
whereas co-transfer with CD4+CD25+ T cells protected mice from disease. The same year, the 
dominance of suppression by T regulatory (Treg) cells was demonstrated. Taken together, 
these pioneering observations have been an auspicious beginning for the role of Treg cells in 
immune responses. The Foxp3 gene, identified as the master gene of Treg, was first identified 
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as a defective gene in the mouse strain Scurfy (X-linked recessive mutant). Foxp3-mutant 
scurfy mice and Foxp3-deficient mice displayed lethal autoimmune lymphoproliferative 
disease, which results from a defection of CD4+CD25+ Treg cells. Similarly, mutations of 
FOXP3 gene in humans result in the deficiency or dysfunction of CD4+CD25+ Treg cells and 
are responsible for IPEX syndrome, a combination of severe multi-organ autoimmune 
diseases. Moreover, when Foxp3 was ectopically expressed via retroviral gene transfer, non-
Treg cells in mice and in human acquired a Treg cell phenotype. Thus, stable Foxp3 
expression is clearly a pre-requisite for the maintenance of the transcriptional and functional 
program established during Treg cell development. The study of suppressor/regulatory T cells 
represents one of the major areas of research in immunology and almost every published 
paper contains some reference or experiment to the involvement of these cells in every model 
system. Indeed, researches in animal models have demonstrated that adoptive transfer of these 
cells can be used to treat many auto-inflammatory diseases such as type 1 diabetes (T1D), 
inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), multiple sclerosis 
(MS), rheumatoid arthritis (RA) and autoimmune gastrtitis (AG). In addition, Treg therapy 
has been found to be efficacious in controlling allo-responses in the setting of graft versus 
host disease (GvHD), as well as organ and cell transplantation. Thus the modulation of Treg 
cells could provide new strategies in creating transplantation tolerance. A key advance for 
Treg therapy in humans is the finding that Treg cells can be isolated and expanded in vitro 
while maintaining immunoregulatory function. The majority of clinical trials published to 
date have utilized either fresh, immunomagnetic bead-isolated Tregs derived from adult 
blood, since clinical grade cell sorting facilities are not widely available, or the same adult 
Treg cells (or cord blood Treg cells) expanded in vitro. However, the requirement to expand 
Tregs in vitro, to achieve a number necessary for a therapeutic benefit, compromises the 
purity of Treg cells at the end of the culture. Therefore, one of the major goals in Treg therapy 
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is to preserve the purity and suppressive ability of ex vivo expanded Treg preparations limiting 
their potential to produce pro-inflammatory cytokines, particularly when Treg cells are 
exposed to an inflammatory environment in vivo. FOXP3 expression is a good surrogate to 
establish Treg purity, but given current expansion techniques, it is unlikely that Treg cultures 
could be 100% FOXP3+ following expansion. So it will be important to determinate 
“acceptable” levels of contaminations, from both quantitative and qualitative prospectives. 
Although many issues and challenges still need to be addressed in this area, the first results of 
clinical trials applying Treg cells in stem cell transplantation are very encouraging. More new 
informations will be revealed in the the next few years on the safety and efficacy of ex-vivo 
expanded Treg cells as a result of the multicentre Phase I/II study founded by the European 
Union FP7 program, “The ONE study”. 
Given the importance of FOXP3 in Treg cell development and function, it becomes essential 
to elucidate the mechanisms by which FOXP3 acts in these cells in order to use them as a 
cellular therapy. Thus, this thesis has two major goals: the first was to undestand the function 
of FOXP3 on target gene expression, and the second was to develop a protocl for the potential 
clinical application of FOXP3-expressing Treg cells. Consequently, the thesis has been 
divided in two parts. The first part contains excerpts from the article entitled “FOXP3 
Forkhead Transcription Factor FOXP3 up-regulates CD25 expression through cooperation 
with RelA/NF-kB” published in PloS ONE, Volume 7, October 2012. Indeed I collaborated 
with the first author, Cristina Camperio, in performing some experiments of this work 
coordinated by Prof. Enza Piccolella during my first two years of PhD course in Italy at 
Department of Biology and Biotechnology “Charles Darwin”. The research in the second part 
of this thesis was conducted under the supervision of Prof. Giovanna Lombardi at Department 
of Transplantation Immunology and Mucosal Biology, King’s College London during my last 
year of PhD course as foreign student in UK I collaborated with Dr. Cristiano Scottà that 
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introduced me to the separation and ex vivo expansion of Treg cell lines investigating 
phenotype, stability and function in vitro. The article containing the collected results, entitled 
“ Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive 
qualities of human CD4+CD25+FOXP3+ Treg subpopulation”, was written by Dr. Cristiano 
Scottà and published in Haematologica Journal, December 2012. 
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Abstract 
The immune system requires a network of regulatory mechanisms that enable the host 
to maintain immune regulation, homeostasis and tolerance. A functionally committed 
CD4+CD25+FOXP3+ T cells subset (Treg cells) have a key role in determining the outcomes 
of protective immunity to a spectrum of foreign antigens while maintaining tolerance to self-
antigens and suppressing excessive inflammation that can cause pathology. The transcription 
factor forkhead P3 (FOXP3) is highly expressed in Treg cells and it is critical for their 
suppressive function. The importance of FOXP3 is demonstrated in humans with a severe 
autoimmunity disease called immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) caused by mutations in FOXP3 gene. Therefore, there is an increasing interest 
in manipulating FOXP3 function and/or using CD4+CD25+FOXP3+ Treg cells as cell therapy 
to modify immune responses in cancer, autoimmunity and transplantation. The transcription 
factor FOXP3 has been shown to regulate negatively some genes such as Il2 and positively 
others, such as Cd25 and Ctla4. To better understand the function of FOXP3 as transcriptional 
activator, the regulation of CD25, the IL-2Rα chain, by FOXP3 was investigated (Part I). 
Analyzing a regulatory region of Cd25 promoter, it has found the presence of a κB site and 
two tandem copies of a non-consensus FOXP3 binding site separated at 5’ ends by 19 
nucleotides that allow FOXP3 and NF-κB/RelA subunit binding to DNA. The occupancy of 
the two FOXP3 binding sites in conjunction with NF-κB/RelA binding site occupancy allows 
FOXP3 to function as a positive activator of Cd25 gene. Indeed mutations of both FOXP3 
binding sites such as mutation of κB site on Cd25 promoter abolished FOXP3 activatory 
functions. Moreover, FOXP3 mutation ΔE251, that compromises FOXP3 homotypic 
interactions, failed to trans-activate Cd25 promoter, suggesting that both FOXP3 DNA 
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binding and dimerization are required to trans-activate Cd25 promoter. So, these findings 
identify a novel mechanism by which RelA and FOXP3 cooperate to mediate transcriptional 
regulation of target genes and characterize a region on Cd25 promoter where FOXP3 dimer 
could bridge intra-molecularly two DNA sites and trans- activate Cd25 gene. Then the 
possibility of using ex vivo expanded CD4+CD25+FOXP3+ regulatory T cells as cell therapy 
was investigated (Part II). The ability to isolate and expand human Treg cells is crucial for 
their use in the clinic and many questions regarding the stability of phenotype and function of 
the transferred Tregs during inflammation remained unresolved. In this study it has been 
developed a protocol for the expansion of clinically useful numbers of functionally 
suppressive and stable human Treg cells. CD4+CD25+FOXP3+ Treg cells were expanded in 
vitro with rapamycin (RAPA) and/or all-trans-retinoic acid (ATRA) and then characterized 
under inflammatory conditions in vitro. The addition of RAPA to Treg cultures confirmed the 
generation of high numbers of suppressive and stable Tregs in vitro. In contrast, ATRA-
treatment generated Treg cells which retained the capacity to secrete pro-inflammatory 
cytokine IL-17. However, combined use of RAPA and ATRA abolishes IL-17 production and 
confered a specific chemokine receptor homing profile upon Treg cell preparations. 
Moreover, the use of purified Treg subpopulations provided direct evidence that RAPA could 
confer an early selective advantage to CD45RA+ Treg subset, while ATRA favored CD45RA- 
Treg subset expansion. So, the expansion of Treg cells using RAPA and ATRA drug 
combinations provided a new approach for large-scale generation of functionally potent and 
phenotypically stable human Treg cells, rendering them safe for clinical use. All together, the 
results reported in this thesis sheds light on the ability of FOXP3 in regulating the expression 
of CD25 molecule and helps pave the way for use Treg cell therapy in clinic.  
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1: General  Introduction 
1.1. Immune tolerance and “suppressor” T cells: history  
A hallmark of the adaptive immune system is the generation of diverse immune 
receptors for the anticipated encounter with rapidly evolving pathogens. This powerful 
strategy for host defense brings considerable challenges. Because T cell receptors (TCRs) are 
selected by highly diverse endogenous ligands, i.e. self-peptide-MHC complexes, potentially 
pathogenic auto-reactive T cells can be generated. Hence, adaptive immunity requires a 
tightly controlled equilibrium between mounting deleterious responses against self, food 
antigens and commensal microorganisms (self-tolerance) while at the same time preserving 
the potential to generate immune responses against pathogens.  From an evolutionary point of 
view, the importance of immune tolerance is proved by multiple non-redundant mechanisms 
designated to control these two different immunological demands. Negative selection of T 
cells in the thymus (central tolerance) leads to elimination or inactivation of those T cells 
reactive to self-antigens above a threshold of affinity for self-antigens-MHC-complexes 
(Kappler et al., 1987). Nevertheless, although central tolerance is responsible for 
neutralization of most high-affinity T cells recognizing self, some auto-reactive T cells fail to 
undergo deletion and they become part of the peripheral T-cell repertoire (Starr et al., 2003). 
Therefore, in order to prevent the development of autoimmune diseases, the immune system 
has devised additional check points to limit the activation of mature self-reactive T cells once 
they have reached the peripheral lymphoid organs. Peripheral tolerance mechanisms provide a 
second level of control to restrain potentially auto-reactive T cells which escape from the 
thymus (Wood K.J., 1996). This is important not only because thymic negative selection is 
stochastic, based on the affinity thresholds, but also because not all self-antigens are 
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expressed in the thymus. In addition to clonal deletion of auto-reactive T cells, chronic 
engagement of TCR by self antigens induces a state of long-term hypo-responsiveness in T 
cells termed “anergy”, characterized by an active repression of TCR signaling and IL-2 
expression. Peripheral tolerance is also reinforced by the requirement of simultaneous 
engagement of TCR by a cognate peptide-MHC complex and the T cell co-stimulatory 
receptor CD28 by CD80 and CD86 (Lenschow et al., 1996). CD80 and CD86 are induced on 
antigen-presenting cells (APCs) upon the activation of innate immune receptors directly in 
response to microbial or viral products or through sensors of metabolic changes invoked by 
microorganisms. However, mechanisms of tolerance operating in a cell-intrinsic manner, 
termed “recessive tolerance”, and the two-signal requirement for the induction of a productive 
immune response, appeared insufficient to counter the threat of immune-mediated pathology. 
The idea of T cell-mediated suppression of immune responses was not new for the 
immunologists. In the late 1960s, the research by Nishizuka and Sakakura led to the finding 
that the normal immune system naturally harbors a particular population of thymic derived 
cells with autoimmune-suppressive activity. They showed that neonatal thymectomy of 
normal mice between day 2 and 4 after birth resulted in the destruction of ovaries, which they 
first supposed to be due to deficiency of a certain ovary-tropic hormone secreted by the 
thymus, hence was called “ovarian dysgenesis” (Nishizuka and Sakakura, 1969). Such 
destruction of ovaries was not be observed when thymectomy was performed after one week 
of life indicating that a thymic derived cell subset, arising after 3 days of life, was involved in 
the prevention of autoimmune oophoritis. Gershon and Kondo demonstrated subsequently 
that lymphocytes deriving from the thymus in mice could prevent specific immune responses 
against exogenous antigens and that spleen cells derived from mice that had become tolerant 
after infusion of T cells, could induce tolerance again when transferred to another mouse. This 
ability to transfer tolerance using cells has been called "infectious tolerance" by Gershon in 
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1971 (Gershon and Kondo, 1970). Since these findings by Nishizuka et al. and Gershon et al., 
intense research has focused on the characterization of suppressor T cells. The studies over 
the following years showed several types of suppressor T cells: some were antigen-specific, 
others being nonspecific; some secreted antigen-specific suppressive factors and others 
nonspecific ones. Moreover, these suppressor populations varied in phenotype and mode of 
suppression (Green et al., 1983). The phenotype of suppressor T cells, assessed by the 
expression of Lyt-1 (CD5) and Lyt-2 (CD8), was on the most part Lyt-2+, corresponding to 
CD8+, while some of them, in particular those suppressing delayed type hypersensitivity, were 
Lyt-1+2- , corresponding to CD4+ cells. CD8+ suppressor T cells expressed the I-J molecule, 
supposed to be a key suppressor molecule associated with their suppressive function. Active 
research of suppressor T cells quite abruptly collapsed in the mid 1980s when scrutiny of the 
mouse MHC gene, by molecular biology techniques, showed no existence of the I-J region, 
which was assumed to encode the  I-J molecule and locate within the MHC gene complex 
(Kronenberg et al., 1983). With this bewildering I-J episode as a turning point, immunologists 
interest in suppressor T cells rapidly waned, forming, in the late 1980s and early 90s, an 
atmosphere in which they even shied away from using the word “suppressor T cells” in 
interpreting suppressive immunological phenomena (Bloom et al., 1992). There were also 
other reasons for this decline in the study; i.e. failure in finding reliable markers for 
distinguishing suppressor T cells from other T cells; ambiguity in the molecular basis of 
suppression and difficulty in preparing antigen-specific suppressor T cell clones amenable to 
fine cellular and molecular analyses. Furthermore, immunologists failed to obtain definitive 
evidence for anomaly of suppressor T cells as a primary cause of any immunological disease. 
Then, approaches to immunologic tolerance with new molecular tools, such as TCR 
subfamily-specific mAb and TCR-transgenic mice, in the late 80s to the early 90s 
demonstrated clonal deletion, and anergy, as key mechanisms of immunologic tolerance 
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(Kisielow et al., 1988). A culmination of this work came in 1995 when Sakaguchi et al. 
identified a subset of CD4+ T cells expressing high amounts of CD25 (interleukin 2 receptor 
α-chain) which constituted 5-10% of peripheral CD4+T cells (Sakaguchi et al., 1995; Asano et 
al., 1996). These cells were able to prevent autoimmunity upon transfer into day-3 
thymectomized mice and, in other experimental models of autoimmunity, inhibit transplant 
rejection. In addition to their capacity to prevent autoimmunity in vivo, these cells were 
shown to suppress the proliferation of activated CD4+ T and their IL-2 production in vitro in 
co-culture suppression assay (Thornton and Shevach, 1998; Takahashi et al., 1998) . This key 
finding led to denomination of CD4+CD25+ T cells as regulatory T cells (Treg cells). The 
presence of a subset of CD25+CD4+ single-positive thymocytes with suppressive ability 
indicated that CD25+ Treg cells differentiate in the thymus. Although the discovery of CD25 
as a useful marker for the functional analyses of these cells following their isolation from 
normal naïve animals, several studies revealed that the molecule was not a mere marker for 
natural Treg cells because of its up-regulation in all activated T cells. The inability to 
discriminate between tolerance- and inflammation-promoting cells during the immune 
response impeded the understanding of dominant tolerance and its mechanistic aspects. 
Furthermore, it was proposed that CD25-expressing Treg cells represented a state of 
activation of conventional CD4+ T cells and their ability to down-modulate the immune 
response occurs because of competition for IL-2. The discovery in mice that CD4+ T cells 
bearing α-chain of IL-2 receptor (CD25) could prevent autoimmunity, led researches in 
human immunology to look for the human counterpart of murine Treg cells. Human Treg cells 
were identified by several groups in 2001 confirming that Treg cells had high levels of CD25 
and suppressive capacity in vitro. Furthermore, it has been subsequently demonstrated that 
Treg cells not only suppressed the proliferation of responder T cells in vitro, but also 
conferred suppressive capacity to suppressed responder cells. This finding has been 
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considered the mechanism underlying the “infectious tolerance” described by Gershon 40 
years earlier. Together these evidences prompted exploration of genetic mechanisms 
underlying differentiation and function of Treg cells. These studies were facilitated by the 
discovery of X chromosome encoded transcription factor Foxp3 and its loss of function 
mutations in mice leading to a severe multi-organ autoimmune disease (Brunkow et al., 2001; 
Chatila et al., 2000). In humans, mutation of FOXP3 gene resulted in the deficiency or 
dysfunction of CD4+CD25+ Treg cells and similarly caused a inflammatory disorder called 
IPEX (Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) (Bennet 
et al., 2001). The fact that in both humans and mice only FOXP3 and Foxp3 mutant males 
respectively but not heterozygote female carries were affected and the systemic nature of 
immune-mediated lesions, were consistent with an idea that mutations in this gene could 
impair differentiation or function of CD4+CD25+ T cells. 
 
1.2. Role of FOXP3 in the development of Treg cells 
1.2.1. FOXP3 expression and Treg lineage commitment 
Supporting the role for FOXP3 in Treg cell commitment came from the analysis of 
CD4+CD25+ T cell populations in the thymus and peripheral lymphoid organs of mixed bone 
marrow chimeras generated upon transfer of Foxp3-deficient and allelically marked wild-type 
bone marrow into T cell-deficient mice. The recipient mice were free of lymphoproliferative 
disease and immune-mediated tissue lesions, and CD4+CD25+ Treg cells were generated only 
from Foxp3-sufficient, but not-deficient precursor cells (Fontenot et al., 2003).This evidence 
demonstrated therefore that an absolute requirement for Foxp3 in Treg cell differentiation in 
the thymus. Moreover, retroviral transfer of the Foxp3 gene into activated peripheral 
 18 
CD4+CD25- T cells also conferred suppressor function and Treg cell surface phenotype 
(Fontenot et al., 2003; Hori et al., 2003). The level of Foxp3 expression in murine Treg cells 
is therefore critical for suppressive function, given that experimentally induced reduction in 
Foxp3 amounts resulted in decreased function. In opposition to mice, FOXP3 expression in 
humans does not allow the unambiguous identification of Treg cells. As FOXP3 is induced 
during TCR stimulation in conventional CD4+ T cells, in much the same manner as CD25, 
there is some debate as to whether the induced CD4+CD25+ FOXP3+ population is 
suppressive or anergic (Allan et al., 2007; Gavin et al., 2006; Wang et al., 2007). One further 
level of complexity compared to murine system has been unveiled with the description of 
CD4+CD25hi cells expressing FOXP3 with naïve phenotype (Valmori et al., 2005; Miyara et 
al., 2009). However, although both in mice and humans the transcriptional factor FOXP3 
plays a pivotal role for the development and suppressive ability of Treg cells, its biological 
function is still incompletely understood. 
 
1.2.2. Requirements for FOXP3 expression 
Although various signals inducing FOXP3 have been identified, the precise 
mechanisms by which the expression of this protein is controlled in Treg cells are not still 
understood. So far, it has been established that the synergistic action of signaling pathways 
including signals downstream of TCR, co-stimulatory molecules and cytokine receptors, 
converge to active FOXP3 gene locus. However it is unclear the relative contribute of these 
different signals capable of inducing FOXP3 in thymocytes compared to naïve peripheral 
CD4+ T cells. 
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1.2.2.1. TCR signaling pathway 
During thymic differentiation, variations in TCR signaling characteristics, such as 
functional avidity and duration, are central determinants of T cell lineage fate determination 
and differentiation of specialized T cell subsets. It is not unexpected then, TCR signaling is 
pivotal for FOXP3 induction and Treg cell lineage commitment. TCR cross- linking, in 
human cells, triggers proximal signaling events that lead to the binding of the transcription 
factors Nuclear Factor of Activated T cells (NFAT) and Activator Protein 1 (AP-1) to the 
FOXP3 promoter or enhancer regions contributing to its transcription (Mantel et al., 2006). 
Consistent with this view cyclosporine A (CsA), that blocks the calcineurin pathway and 
NFAT, completely inhibithed FOXP3 expression. In contrast, inhibitors of mitogen-activated 
protein kinase (MAPK) that affect AP-1, inhibited only partially the induction of FOXP3 .The 
decrement of FOXP3 expression by CsA in Treg cells suggests that NFAT may be required 
while AP-1 may be dispensable for Treg production (Mantel et al., 2006 ; Wang et al., 2006). 
The requirement for TCR stimulation in FOXP3 expression and thymic development of Treg 
cells is illustrated by the failure of TCR transgenic T cells to express FOXP3 in the absence of 
endogenous TCR rearrangements (Bautista et al., 2009). Stimulation of adoptively transferred 
TCR transgenic T cells demonstrated that peripheral Foxp3 induction is associated with 
suboptimal activation (increased CTLA-4 and decreased CD28 signaling) and inversely 
correlates with proliferation (Waldmann et al., 2008; Rudensky, 2006). Consistent with these 
findings, studies in vitro have suggested that extensive TCR stimulation is detrimental for 
Foxp3 expression. In this regard, Sauer et al. showed that a constitutive o prolonged signaling 
through the PI3K/Akt/mTOR pathway, which is downstream of the TCR, antagonizes the 
induction of FOXP3 in peripheral T cells. Inhibition of this signaling network conferred de 
novo FOXP3 expression and promoted Treg cell maturation (Sauer et al., 2008). Indeed, 
PI3K/Akt/mTOR pathway is attenuated in nTreg versus conventional T cells (Bensinger et al., 
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2004; Walsh et al., 2006; Crellin, 2007). Diminished activation of this signaling appears to be 
important to maintain active levels of FOXO1 and FOXO3. These transcriptional factors bind 
to the FOXP3 promoter to facilitate FOXP3 expression (Ouyang et al., 2010; Harada et al., 
2010; Kerdiles et al., 2010). When the PI3K pathway is active, FOXO1 and FOXO3 are 
inactivated by phosphorylation and cannot support FOXP3 transcription. Collectively, these 
data suggest that weak TCR stimulation is favorable for the peripheral induction of FOXP3.  
 
1.2.2.2. CD28 co-stimulation 
Another important signal required for FOXP3 gene activation and an efficient 
generation of Treg cells in the thymus is co-stimulatory signaling through CD28/B7 pathway. 
This notion is supported by the evidence that CD28-deficient mice contained marked 
reduction in CD25+Foxp3-Treg precursors, suggesting an “early” requirement of CD28 co-
stimulation simultaneous to or in relatively close temporal proximity to the presumed 
initiating TCR signal (Tai et al., 2005; Lio et al., 2010; Vang et al., 2010). Similarly, 
expression of active STAT5, a target of IL-2 signaling, in CD28 -/- mice, improved thymic 
development of Treg cells. One interpretation of these data is that impaired CD28 co-
stimulation leads to lower IL-2 responsible for defective nTreg development and homeostasis 
(Burchill et al., 2008). However, beyond its possible contribution to optimize IL-2 production, 
CD28 provides an intrinsic signal for Treg cell differentiation program by directly inducing 
FOXP3 expression (Scottà et al., 2008). Generally, CD28 addresses several downstream 
signaling cascade through distinct SH2- or SH3-domain-bindingg motifs in its cytoplasmic 
tail that mediate among others interactions with Lck and PI3K pathway respectively. 
However, the ability of CD28 to support efficient thymic Treg cell generation has been found 
to not require an intact PI3K-binding motif (Tai et al., 2005; Vang et al., 2010). Consistent 
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with this, PI3K-signaling through Akt and mTOR, antagonizes nTreg differentiation by 
sequestering FOXO1/FOXO3a from the nucleus (Delgoffe et al., 2009; Haxhinasto et al., 
2008; Ouyang et al., 2010; Sauer et al., 2008). On the contrary, the Lck-interacting P187 YAPP 
motif in the cytoplasmic tail of CD28 seems to be crucial for thymic Treg differentiation (Tai 
et al., 2005). Therefore, CD28, in conjugation with TCR stimulation, may generate signals 
distinct from those elicited by TCR triggering alone. For instance, the activation of the 
nuclear factor-κB (NF-κB) pathway and NF-κB-regulated genes is a unique feature of CD28 
(Tuosto, 2011). Cross-linking of TCR together with CD28 stimulation in T cells, was found to 
activate nuclear factor-κB (NF-κB), whereas TCR alone was unable to do so (Marinari et al., 
2004; Takeda et al., 2008). Thus, NF-κB may be considered the most relevant CD28 
biochemical target. Many recent data strongly support the view that NF-κB regulates FOXP3 
expression and serves a bona fide “lineage-instructing” function (Deenick et al., 2010; 
Isomura et al., 2009; Visekruna et al., 2010). Consistent with a role of NF-κB activation in 
Treg development, deletion of upstream components of this pathway, PKCθ, Bcl-10 or 
CARMA-1, resulted in a significantly reduction of the number of nTreg cells both in the 
thymus and in periphery (Schmidt-Supprian et al., 2004; Gupta et al., 2008 Medoff et al., 
2009; Barnes et al., 2009). Intriguingly, recent report by Long et al. has provided the evidence 
demonstrating a link between these signaling molecules and NF-κB in regulation of Foxp3 
expression. In a transgenic mouse model, NF-κB activity was reduced by mutated non-
degradable inhibitor IκBα, which sequesters NF-κB in the cytoplasm of non-activated cells, 
and both percentage and absolute numbers of Foxp3+ thymocytes were reduced (Long et al., 
2009). Furthermore, enhancing NF-κB signal could rescue Foxp3 expression in CARMA-1 
deficient mice, indicating that the impairment in thymic Foxp3 expression and Treg 
development is mediated by defective NF-κB activity. Additionally, transgenic enhancement 
of NF-κB signaling has been demonstrated to be able to bypass the requirement of TCR 
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signals to induce FOXP3 expression in the thymocytes and peripheral mature T cells (Long et 
al., 2009). Thus, these findings collectively imply a relationship between these intermediates 
signaling molecules, PKCθ, Bcl-10 and CARMA-1, and NF-κB in regulation of FOXP3 
expression. Although these studies emphasize the importance of NF-κB signaling in nTreg 
generation, the specific NF-κB family members, required for Treg cell differentiation and 
their specific mechanisms of actions, remain to be elucidated. NF-κB can be composed as a 
combination of five related proteins, RelA/p65, c-Rel, RelB, p50 and p52 that form homo-and 
hetero-dimeric complexes (Natoli et al., 2005). Recently, it was demonstrated that c-Rel has a 
critical cell-intrinsic role in FOXP3 induction by binding to a conserved non-coding sequence 
(CNS) in Foxp3 promoter (Ruan et al., 2009; Zheng et al., 2010). The link between  this CNS 
and c-Rel in Foxp3 induction comes from the evidence that Foxp3 gene activation of CNS- 
and c-Rel-deficient thymocytes is significantly impaired (Zheng et al., 2010). However, the 
molecular mechanism of CNS- and c-Rel-mediated Foxp3 induction remains to be elucidated. 
One possibility is that c-Rel binding to CNS facilitates Foxp3 locus opening and, 
consequently, the recruitment of numerous regulators of Foxp3 gene expression, including 
factors involved in chromatin remodeling, acetyl-transferases, histone deacetylases and 
sequence-specific transcription factors (Rao et al., 2003). Another interpretation could be that 
following binding to CNS, c-Rel forms a multifactiorial complex, called enhanceosome, with 
other factors to control Foxp3 promoter induction (Ruan et al., 2009). However, whether or 
not c-Rel enhanceosome formation depends on this CNS is still unclear. In addition, other 
evidences demonstrated c-Rel binding to another CNS, a regulatory element required for 
heritable maintenance of Foxp3 expression but dispensable for its induction, suggesting that 
c-Rel may contribute also to the maintenance of Foxp3 expression (Zheng et al., 2010). 
However, controversial finding concerning the role of other NF-κB family members are 
present in the literature. For instance, Ruan et al (2009). suggested that c-Rel dimerizes with 
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p65/RelA subunit but not p50 or RelB, consistent with the evidence that p50-deficient mice 
have normal numbers of nTreg cells (Deenick et al., 2010) However, Long et al. (2009) did 
not detect a substantial increase in p65 binding in any of potential NF-κB sites in Foxp3 
promoter. Conversely, Piccolella lab recently found that human FOXP3 promoter contains at 
least three functional and not redundant κB sites for RelA binding that contributes to FOXP3 
promoter activation and its expression (Soligo et al., 2011). However these sites could be not 
required for c-Rel mediated FOXP3 activation, since their deletion did not modify the effect 
of c-Rel on FOXP3 promoter. The reasons for this discrepancy could be various, including 
different stimulation and cell types. Moreover, a high FOXP3 DNA conservation between 
humans and mice was not found, suggesting that murine Foxp3 promoter could be less 
dependent on RelA. Altogether these observations, although contrasting for the contribution 
of NF-κB subunits to FOXP3 promoter regulation, share the evidence that CD28 signaling is 
required for Treg differentiation. Most importantly these data shed light on FOXP3 expression 
is strictly dependent on CD28-mediated NF-κB activation. 
 
1.2.2.3. Cytokyne-receptor signaling 
Cytokine signaling is clearly of paramount importance to Treg differentiation as mice 
with disrupted IL-2 signaling pathways (i.e. IL-2 or IL-2Rα chain knockout stains) have no 
Treg cells (Sadlack et al., 1993). By the same token, TGF-β is a critical factor in the 
peripheral commitment of naïve T cells to the Treg phenotype (Chen et al., 2003; Zheng et al., 
2004). 
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1.2.2.3.1. IL-2R-STAT5 pathway 
IL-2 signal transduction is mediated by the JAK-STAT (Janus Kinase-Signal 
Transducer and Activator of Transcription) pathway involving JAK1, JAK3 and STAT5. 
Briefly, JAK-STAT pathway is a receptor-coupled signal transduction mechanism linking 
cytokine-interactions to gene expression. JAK proteins (JAKs) are present in association with 
the cytoplasmic tails of multimeric cytokine receptors and are activated upon receptor 
dimerisation (Levy and Darnell, 2002; Boulay et al.; 2003). Activated JAKs phosporylate the 
cytoplasmic tails of associated cytokine receptors, creating docking sites for the SH2 (Src-
homology-2) domain of STAT proteins (STATs), and then activate the docked STATs through 
tyrosine phophorylation. Activated STATs dimerise and translocate to the nucleus to regulate 
gene transcription by binding to specific promoter regions. STAT5 activation is the main IL-
2R-dependent pathway active in Treg cells. The importance of this molecule in Treg biology 
comes from the evidence that mice deficient in STAT5 exhibit a substantial decrease of Treg 
cells and largely recapitulate the phenotype of IL-2- and IL-2R deficient mice (i.e. lost of 
CD25 expression, reduced levels of Foxp3 and impaired number of immature thymic nTreg 
cells) (Baier et al., 2007; Malek et al., 2002). In addition, STAT5 has also been found to be 
required for the optimal induction of FOXP3 in vitro. The role of this pathway in Foxp3 
regulation is further supported by the evidence that at the molecular level, STAT5 directly 
regulate Foxp3 expression by binding to the Foxp3 promoter in vitro (Yao et al., 2007). As 
expected, Stat5 conditional allele ablation in double-positive (DP) thymocytes resulted in a 
severe reduction in Foxp3+ CD4 single-positive (SP) thymocytes (Burchill et al., 2007; Yao et 
al., 2007). In complementary gain-of-function studies, expression of a constitutively active 
STAT5 entailed expansion of Treg cells and rescued Treg cell numbers in the absence of IL-2 
(Burchill et al., 2008; Burchill et al., 2003). Nevertheless, the exact mechanism of how IL-2R 
signaling impinges on Treg differentiation remains to be fully established. Although the role 
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of IL-2R-STAT5 signaling for the differentiation of Treg cells is well-proved, it is still unclear 
if STAT5 directly drives FOXP3 transcription, induces changes in the chromatin at the 
FOXP3 locus, or instead promotes survival or expansion of Treg cells and/or their precursors. 
In vivo, the quantitative level of IL-2R signaling that leads to Treg maturation is set a low 
threshold. Therefore, the ability of developing nTreg cells to productively sense low IL-2 is 
likely important as IL-2 producing cells are rare in the thymus. This unique sensitivity of Treg 
precursors to minimal IL-2R signaling ensure that key molecules of mature Treg cells, such as 
FOXP3, CD25 and CTLA-4 are readily expressed (Yu et al., 2009). IL-2 is also required for 
TGF-β mediated induction of FOXP3 in peripheral conventional CD4+T cells in vitro. The 
culture of these cells with TGF-β in the absence of IL-2 does not yield iTreg cells (Zheng et 
al., 2007). This function of IL-2 is not-redundant and cannot be substituted by other γc-
dependent cytokines. However, it is still unclear the extent IL-2R signaling is required for 
iTreg development in vivo. Treg cells show, therefore, an obligate requirement, both in vivo 
and in vitro, for IL-2 and the structurally-related IL-2 family members, IL-15 and IL-7, for 
maintenance of FOXP3 expression and suppressive function (Bayer et al., 2008; Yates et al., 
2007). 
1.2.2.3.2. Transforming growth factor - β (TGF-β)- pathway  
The transforming growth factor beta (TGF-β) is a pleiotropic anti-inflammatory 
cytokine that regulates multiple aspects of T cell development, homeostasis, tolerance and 
immune responses (Li and Flavell, 2008). Compelling evidence indicate that this cytokine, 
concomitant with TCR stimulation, induces Foxp3 expression in naïve CD4+CD25-FOXP3- T 
cells and converts them in FOXP3+ Treg cells (Kretschmer et al., 2005; Chen et al., 2003; 
Zheng et al., 2004; Bettelli et al., 2006) These induced Treg cells (iTreg) are phenotypically 
and functionally resemble naturally-occurring Treg cells (nTreg) cells in vitro (Chen et al., 
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2003; Fantini et al., 2004; Fu et al., 2004) and are effective at preventing organ-specific 
autoimmunity in a murine model of autoimmune gastritis (DiPaolo et al., 2007). The notion 
that TGF-β signal is required for the induction of Foxp3 expression is also supported by the 
evidence that CD4+CD25- T cells deficient in TGF-β signaling could not be converted to 
Foxp3+ Treg cells in vivo or in vitro (Liu et al., 2008). In human, although FOXP3 expression 
is also driven by TGF-β in CD4+CD25- T cells (Amarnath et al., 2007; Fantini et al., 2004), 
the induced FOXP3+ T cells are neither anergic nor suppressive and produce high levels of IL-
2 and IFN-γ (Tran et al., 2007). It seems that the conversion of FOXP3+ T cells with Treg 
phenotype and function is more complex in human and FOXP3 expression alone is not 
sufficient to confer the regulatory phenotype (Wan and Flavell, 2007; Wang et al., 2007). 
Both the transcription factors TGF-β-inducible early gene 1 (TIEG1) and Mother Agaist 
Decapentaplegic 3 (Smad3) bind to promoter regions in FOXP3 gene and enhance its 
expression (Tone et al., 2008). In particular, Smad3 binds to the intronic enhancer 1 of 
FOXP3 locus and this binding is required for histone acetylation and function of the enhancer 
(Tone et al., 2008). However, unlike that occurs in nTreg cells, FOXP3 expression in iTreg 
cells has been shown to be transient both in vivo and in vitro (Floess et al., 2007; Polansky et 
al., 2008). This unstable FOXP3 expression maybe correlates with the relative lack of 
demethylation of CpG-rich regions in FOXP3 locus in iTreg cells (Josefowicz et al., 2009; 
Polansky et al., 2008; Kim et al., 2007). The induction of FOXP3 expression by TGF-β is also 
influenced by many other factors and/or cytokines: IL-2 is involved in the generation of iTreg 
cells (Zheng et al., 2007); CTLA-4 ligation of CD80 is also required for TGF-β to induce 
CD4+CD25- T cells to express FOXP3 (Zheng et al., 2006); and retinoic acid (RA) has been 
shown to enhance TGF-β-induced expression of FOXP3 (Sun et al., 2007; Mucida et al., 
2007; Coombes et al., 2007; Laurence et al., 2007). In contrast, IL-4 suppress iTerg induction 
and IL-6 prevents the conversion of naïve CD4+CD25- T cells into FOXP3+ Treg cells 
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switching the differentiation program towards Th17 cells (Hadjur et al., 2009; Bettelli et al., 
2008). 
 
1.3. Molecular characteristic of transcription factor FOXP3   
1.3.1. Identification of FOXP3 gene  
               The Foxp3 gene was identified in 2001 as the disease-causative gene in Scurfy mice, 
which spontaneously developed a fatal autoimmune lymphoproliferative syndrome (Brunkow 
et al., 2001; Khattri et al., 2003; Fontenot et al., 2003)). This gene, which was found to map 
to a gene locus on the X chromosome, was described as a new member of the 
forkhead/winged-helix family of transcriptional factors (Bennett et al., 2000). The Foxp3 
gene is highly conserved between species and mutations in the human FOXP3 gene, the 
ortholog of murine Foxp3, was found to be the cause of a similar human disease called IPEX 
(immune dysregulation, polyendocrinopathy, enteropathy X-linked) which resemble the 
diseases observed following depletion of CD4+CD25+ T cells in rodents (Powell and 1982; 
Bennett et al., 2001; Wildin et al., 2001). Mice and humans with a loss-of-function mutation 
in  Foxp3 and FOXP3 genes respectively, are afflicted with a fatal, early-onset, T cell-
dependent, lymphoproliferative, immune-mediated disorder manifested by diabetes, 
thyroiditis, hemolytic anemia, hyper-IgE syndrome, exfoliative dermatitis, splenomegaly, 
lymphadenopathy, and cytokine storm (Gambineri et al., 2003). The disease affects only 
hemizygous mutant males and not heterozygous female carrying Foxp3 mutations because of 
random X-chromosome inactivation which ensure that some T cells express a wild-type 
Foxp3 allele (Goldfrey et al., 1994). Both the mouse and human diseases lack discrete 
circulating Treg cells, suggesting that Foxp3 and FOXP3 are essential for normal Treg cell 
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development in two species respectively (Hori et al., 2003; Fontenot et al., 2003). This notion 
was strengthened by studies in mice which  reveled stable expression of high amounts of 
Foxp3 in CD4+CD25+ Treg cells, but not in naïve CD4+CD25- T cells or in activated CD4+ T 
cells (Hori et al., 2003; Fontenot et al., 2003; Khattri et al., 2003). Mutations that inactivate 
Foxp3 gene in mature Treg cells results in a loss over time of suppressor function, 
characteristic Treg cell surface markers and acquisition of effector T cell properties including 
production of immune response-promoting cytokines IL-2, IL-4, IL-17, and IFN-γ (Williams 
and Rudensky, 2007). The identification of heritable mutations in FOXP3 gene as the cause of 
IPEX, provided the clearest demonstration to date that, defects in a single gene could 
constituently disrupt immune homeostasis and lead to severe autoimmunity. They also 
suggested that this gene is involved in the dominant regulation of immune responses to self-
antigens. Therefore, sequencing of FOXP3 gene is still considered to be the gold standard for 
diagnosis of IPEX (Gambineri et al., 2008). 
 
 
 
 
 
 
 
 
 29 
1.3.2. FOXP3 locus 
    Figure 1. Foxp3 locus in developing thymic Treg cells 
     
 
 
    Adapted from Klein & Jovanovic. Seminars in Immunology, 2011 
 
 
1.3.2.1.  TGF-β-sensitive element (CNS1) 
              FOXP3 locus, in addition to having a promoter highly conserved between humans, 
mice and rats (Mantel et al., 2006) contains three proximal intronic conserved non-coding 
DNA sequences (CNS) that have a pivotal role in regulating FOXP3 gene. Because the 
nomenclatures used in various reports differ,  I will refer to these elements by their position 
relative to the FOXP3 transcription start site (TSS). A second highly conserved “enhancer” 
region in FOXP3 locus has been identified as a TGF-β-sensitive element (referred to as CNS1 
in Zheng et al., 2010). This sequence, located approximately +2kb downstream of the 
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promoter, contains binding sites for transcription factors, such as NFAT and SMADs (Tone et 
al., 2008). The increased levels of acetylated histone H4 found in CNS1, account for an 
accessible state of chromatin in both nTreg and iTreg cells (Marie et al., 2006; Tone et al., 
2008). Moreover, TGF-β-induced chromatin remodeling at this locus could affect the 
accessibility of the upstream FOXP3 promoter, as the level of promoter demethylation was 
found to be slightly increased in TGF-β-treated mouse T cells (Kim et al., 2007; Sauer et al., 
2008). However, the activation-induced opening of the FOXP3 promoter might have been due 
to low levels of TGF-β in the culture medium as neutralization of TGF-β completely 
abrogated the transient FOXP3 expression in human T cells (Tran et al., 2007). This evidence 
suggests that a different sensitivity to low levels of TGF-β in mouse and human T cells could 
account for a different activation-induced FOXP3 expression observed in the two species. 
 
1.3.2.2. Treg-specific-demethylated-region (TSDR) or CNS2 
              The most striking differences regarding the methylation pattern at FOXP3 locus, 
have been observed in a third, highly conserved CpG dinucletide-rich region identified both in 
mouse and human cells. The TSDR (referred to as CNS2 Zheng et al., 2010) is located in an 
intronic region approximately 4.5kb downstream of the TSS. It is fully demethylated in Treg 
cells and methylated in conventional T cells (Floess et al., 2007; Kim et al., 2007; Baron et 
al., 2007; Nagar et al., 2008). CNS2 has an enhancer activity markedly reduced following 
methylation (Polansky et al., 2008). This evidence is supported by the finding that the 
transcription factor CREB binds to TSDR when it is demethylated (Kim et al., 2007). Taken 
together, these data suggest a role for DNA methylation in the molecular regulation of FOXP3 
expression. TSDR demethylation does not act as an on/off switch, but rather determinates 
FOXP3 expression stability. This view is consistent with the known role of epigenetic 
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regulation in Treg cell lineage commitment. TSDR demethylation corresponds with stability 
of FOXP3 (as in nTreg cells), whereas T cells that express FOXP3 only transiently (TGF-β 
induced Treg cells and recently activated T cells), have a methylated TSDR (Floess et al., 
2007; Polansky et al., 2008). These data are supported by the finding that pharmacological 
inhibition of DNA methyltransferase-1 (DNMT1) in conventional T cells, using the covalent 
inhibitor 5-azacytidine followed by TCR activation, results in stable FOXP3 expression and 
Treg cell phenotype (Kim et al., 2007; Nagar et al., 2008; Polansky et al., 2008). 
 
1.3.2.3. Treg-“pioneer element” CNS3 
               Worthy of notice, the non coding sequence at +7kb (CNS3 in Zheng et al., 2010), 
just downstream of the first coding exon, acts as “pioneer element” in generation of Treg cells 
in the thymus and in periphery. Chromatin modifications, discussed above, at TSDR and 
TGF-β-sensitive enhancer element, coincide with and directly precede FOXP3 expression 
(Zheng et al., 2010). However, as acquisition of an activated chromatin state is coincident 
with FOXP3 expression, it seems unlikely that these regulatory DNA elements would act as 
the early mediators of chromatin remodeling and de novo activation of the FOXP3 locus. 
Instead, a distinct regulatory DNA element might act earlier than CNS1 and CNS2 through 
the reception of appropriate signals. Indeed, CNS3 locus is characterized by chromatin 
modifications, associated with distal regulatory elements, including H3K4me1 and H3K27Ac, 
and accessibility, not only in Treg cells actively expressing FOXP3, but also in both thymic 
and peripheral precursors (Zheng et al., 2010). This evidence suggests that CNS3 is 
implicated in early regulation of FOXP3 locus activation. Consistent with this, CNS3 controls 
the probability of FOXP3 expression among a population of precursor cells (rather than the 
level of FOXP3 expression) and it is bound by the NF-κB family member, c-Rel (Ruan et al., 
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2009). Thus, CNS3 represents a developmentally poised regulatory DNA element that 
function early in FOXP3 locus activation, likely before the other sequences, CNS1 and CNS2. 
Identifying additional regulatory DNA elements, transcription factors and chromatin 
modifying and remodeling complexes and their concerted function with CNS1, CNS2 and 
CNS3 to promote and propagate the activated chromatin state, will allow for the induction 
and maintenance of FOXP3 expression. 
 
1.3.3. FOXP3 promoter 
The human FOXP3 promoter, initially characterized by Mantel et al., is located 6.5 kb 
upstream of the first coding exon, containing six NFAT, AP-1 and three NFkB binding sites 
and a TATA and CAAT box (Mantel et al., 2006; Soligo et al., 2011). Treg cells and resting 
conventional T cells show differences in the epigenetic modifications of FOXP3 promoter in 
both humans and mice: the CpG motifs in FOXP3 promoter were found to be hypo-
methylated in nTreg cells but almost completely methylated in other T cells and only 
incomplete demethylation in TGF-β-induced iTreg cells (Baron et al., 2007; Floess et al., 
2007; Kim and Leonard, 2007; Nagar et al., 2008). Moreover, FOXP3 promoter shows a 
stronger association with acetylated histones in Treg cells, than in conventional T cells, 
indicative of an “open” chromatin configuration allowing the access by key transcriptional 
factors such as AP-1, NFAT, NF-κB and STAT5 (Mantel et al., 2006; Long et al., 2009; 
Isomura et al., 2009; Yao et al., 2007). In addition, murine experiments demonstrated that, 
following in vitro activation of conventional T cells, Foxp3 promoter methylation was 
increased. This structural effect could restrict the accessibility of the promoter and prevent 
Foxp3 induction in these cells. 
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1.3.4. Key structural features of FOXP3 transcriptional factor 
 Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)-
associated FOXP3 mutations have been identified in both the non-coding and coding 
sequences of the FOXP3 gene (Bennett et al., 2001; Wildin et al., 2001; Gambineri et al., 
2008). Point mutations or small in-frame deletions within the coding region of the gene are 
the most informative for elucidating structure/function relationships of specific domains of 
the protein. In humans, FOXP3 is a 431 amino acid (aa) protein consisting of four functional 
domains: an amino terminal proline-rich region (PRR, aa 1-193), a C2H2 zinc finger domain 
(aa 200-223), a leucine zipper motif (LZ, aa 240-261), and a carboxyl-terminal forkhead 
domain (FKH, aa 338-421) (Lopes, 2006). Each of these motifs is involved in the molecular 
function of FOXP3. Therefore, mutations affecting each domain generate a specific signature 
of molecular defects. 
 Figure 2. Schematic diagram of FOXP3 and IPEX mutations along  FOXP3 domains 
         
 Adapted from d’Hennezel et al. J.Med. Genet, 2012 
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1.3.4.1. N-terminal, PRR domain 
 The N-terminal domain is involved in various interactions that are critical for 
multiple aspects of FOXP3 function, including its ability to suppress cytokine production. 
FOXP3 was originally thought to exclusively repress transcription since it inhibited luciferase 
activity driven by an SV40 promoter. However, more recent studies have revealed that this 
factor can also act as an activator of transcription. Chromatin immunoprecipitation combined 
with microarray studies revealed numerous transcriptional targets of FOXP3, including genes 
whose expression is down – regulated (i.e. IL-2 and IFN-γ) and genes whose expression is 
up–regulated (i.e. IL-10, CTLA-4, GITR and CD25) (Chen et al., 2006). The N-terminal 
region of FOXP3 harbors also a canonical LxxLL motif within a.a. 70-105 that allows FOXP3 
to interact with RORα, inhibiting thus RORα -mediated transcriptional activation (Du et al., 
2008). RORα is a transcription factor that is critically involved in the regulation of 
inflammatory Th17 cell development (Cohen et al., 2011). Hence, the fate of a given T cell is 
highly dependent on factors affecting its internal FOXP3/RORα balance, and the loss of 
FOXP3 expression is expected to lead to an inflammatory Th17 phenotype. The N-terminal 
motif of FOXP3 mediates in part the repression of NFAT/AP-1-driven transcriptional 
programme involving IL-2 and IFN-γ gene expression. Therefore, the interaction of FOXP3 
with NFAT/AP-1 complex could affect the maintenance of Treg anergy (Lopes et al., 2006) 
Amino acids 70-105 of FOXP3 contain a lysine-rich, nuclear export sequence, which renders 
it differentially sensitive to lysine acetylation (Wen et al., 1995). Lysine acetylation of FOXP3 
may represent a pivotal mechanism in regulating its function. Indeed, active and acetylated 
FOXP3 is preferentially, but not exclusively, bound to chromatin (Samanta et al., 2008). Such 
acetylation could be mediated by TIP60, a histone acetyltransferase (HAT) that has been 
demonstrated to associate with FOXP3 (Wen et al., 1995; Li et al., 2007). Therefore, TIP60 
may function to enhance the ability of FOXP3 to bind to promoters. Since TIP60 is known to 
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recruit Class II histone deacetylase 7 (HDAC7) in other transcriptional repressor complexes, 
the possibility that FOXP3 also interacts with this protein was investigated. Indeed, co-
immmunprecipitation studies demonstrated that FOXP3 associates with HDAC7 in human 
Treg cells (Li et al., 2007). As for TIP60, the HDAC7-association domain is in the amino 
terminal 1-190 a.a. (Li et al., 2007). Thus, the amino terminal 106-190 a.a are key for the 
ability of FOXP3 to repress transcription via a mechanism that depends on a tri-molecular 
complex of FOXP3, TIP60 and HDAC7. These findings suggests that the function of FOXP3 
is at least partially mediated by modulating the configuration of chromatin, thereby regulating 
access to promoter regions for itself and potentially for other transcription factors. 
 
 1.3.4.2.  Zing-finger domain 
         Amino acids 200-223 encode a classic C2H2 zinc finger. The role of this domain in the 
normal function of FOXP3 is unknown. It could be involved in homo-oligomerisation of the 
protein and mutations that destroy the structure of this motif do not appear to significantly 
affect the ability of FOXP3 to repress gene transcription from the IL-2 promoter (Lopes et al., 
2006). 
 
1.3.4.3. Leucine zipper domain (LZ) 
 The LZ domain (a.a. 240-261) is necessary to mediate FOXP3 homo-oligomerization 
and hetero-oligomerization with another member of the FKH family of transcriptional factors, 
FOXP1. However, this motif is not required in order for FOXP3 to form high molecular 
weight protein complexes (Li et al., 2007). Several IPEX mutations are found in this short 
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interval, the most studied of which is the ΔE251 mutant (Gambineri et al., 2008; Gavin et al., 
2006; Wildin et al., 2002). Either IPEX-derived or experimental disruption of the LZ domain 
leads to a loss in transcriptional regulation by FOXP3 and subsequently of suppression by 
Treg cells (Lopes et al., 2006; Chae et al., 2006; Mailer et al., 2009). In particular, a naturally-
occurring splice variant of FOXP3 lacking both exons 2 and 7, which encodes the LZ domain, 
lacks regulatory properties and has been suggested to play a role in regulating the function of 
the other FOXP3 isoforms by a dominant negative effect (Mailer et al., 2009). Dimerization 
of FOXP3 ensemble is required for its function as a transcriptional regulator. Indeed, recent 
evidences have suggested that FOXP3 does not function as a single molecule, but by forming 
a large supra-molecular complex detected an endogenous FOXP3 complex of more than 500 
kD in size in human T cells, and found FOXP3 can exist as homodimers or homotetramers (Li 
et al., 2007). Although the forkhead domain alone (described in details in the next section) 
may bind to DNA in vitro, mutations of the leucine zipper domain disrupting FOXP3 
dimerization, can substantially reduce the binding of FOXP3 to promoter regions in vivo (Li 
et al., 2007). Finally, the association of FOXP3 with HAT and HDAC proteins is partially 
abrogated in LZ mutants, and the resulting complex also partly loses its ability to bind DNA. 
Moreover, the leucine zipper domain is also important for the interaction between histone 
H5.1 and FOXP3, which cooperatively repress IL-2 transcription in human T cells (Mackey-
Cushman et al., 2011). Therefore, FOXP3 protein ensemble, as well its DNA binding 
properties, could be modulated through oligomerization of the leucine zipper region.  
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 1.3.4.4. DNA-binding, FKH domain 
 The FKH domain spans a.a. 337-421 in the C-terminal region of the protein. Deletion 
of he FKH domain (truncated after a.a. 327) abrogates FOXP3 ability to bind DNA as 
measured by various in vitro DNA-binding assays (Schubert et al., 2001) The importance of 
the FKH domain for in vivo Foxp3 function is demonstrated by the Scurfy mouse in which a 
two-nucleotide insertion in exon 8 of the Foxp3 gene causes a frameshift and premature 
termination codon that deletes the FKH domain (Sakaguchi et al., 2010). This motif interfaces 
with the transcription factors NFAT and NF-κB, and targeted mutations of the NFAT binding 
residues in the FKH domain lead to a loss of IL-2 repression (Wu et al., 2006). Recently, 
Bandukwala and colleagues have solved the crystal structure of the FOXP3/DNA complex 
demonstrating that a segment of the FKH domain forms a domain-swap interface with the 
capacity to simultaneously engage two molecules of DNA (Bandukwala et al., 2011). 
Mutations in the domain-swap interface abrogated FOXP3 dimer formation by the FKH 
domain but did not affect DNA binding. The same authors suggested that FOXP3 exists as a 
dimer of dimers, wherein a pair of FOXP3 molecules forms a domain-swapped dimer through 
their FKH domains and the two domains associate with each other through their ZF-LZ 
regions. The inability of FOXP3 to form a stable dimer was associated with a dramatic loss of 
FOXP3-mediated suppressive function (Bandukwala et al., 2011). 
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Figure 3. Overall structure of the NFAT1: FOXP3:DNA complex 
                                             
 
                                           From Bandukwala et al. Immunity, 2011 
 
 
Predictably, several IPEX mutations directly affect residues that are at domain-swapped 
interface, including F367C, F367L, M370L, F371C, F373V, F373A and F374C, many of 
which are associated with severe clinical outcomes (Gambineri et al., 2008; Wildin et al., 
2001; Bacchetta et al., 2006; Wildin et al., 2002). However, despite recent insights into the 
functions of each FOXP3 domain, the role that each plays in mediating and maintaining Treg 
suppressive capacity under normal physiological circumstances, remains unclear. Indeed, one 
problem may be that many of the assays used to evaluate FOXP3 function in vitro using 
ectopic expression systems may not be able to discern subtle functional abnormalities that are 
evident in vivo when the protein is expressed at  physiological levels. 
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1.3.4.5.The LZ-FKH loop 
 The amino acids between the LZ and FKH domains of FOXP3 (a.a. 261-337) but 
have been shown to be essential for the binding of FOXP3 to RUNX proteins, Runx1, Runx2, 
and Runx3 (Hu et al., 2006). Most investigations are focused on Runx1 since it is expressed 
in Treg and Tconv cells and regulates expression from the IL-2 and IFN-γ promoters (Ono et 
al., 2007). Indeed FOXP3 suppresses Runx1-stimulated IL-2 production in Tconv and Treg 
cells. A mutant form of FOXP3 unable to bind to Runx1 fails to suppress IL-2 production, 
demonstrating that interaction is critical for this function. The importance of Runx1 to Treg 
cell function is further illustrated by the fact that mouse CD4+ T cells transduced with a 
mutant FOXP3 that cannot bind to Runx1 are less suppressive than cells transduced with wild 
type FOXP3, and moreover that knockdown of Runx1 in human Treg cells attenuates their 
suppressive capacity (Ono et al., 2007). Moreover, recent data indicate that interactions 
between Runx1 and Foxp3 are also necessary for Foxp3-mediated inhibition of IL-17-
producing T cells (Zhang et al., 2008). Of note, one of the known point mutations of FOXP3 
that causes IPEX occurs in the Runx1-binding region of FOXP3 and causes a late-onset, mild, 
and spontaneously remitting disease (Bacchetta et al., 2006). 
 
1.3.5. Control of FOXP3 gene expression by epigenetic modifications 
Recently, several groups have observed that epigenetic regulation is crucial for 
controlling FOXP3 locus expression. Epigenetic modifications, which can target histones or 
DNA directly, affect gene transcription by altering the accessibility of distinct DNA regions to 
transcription factors and other DNA-binding molecules. Histones can be modified by site-
specific acetylation and by methylation that are essential for determining the overall 
 40 
chromatin structure. In addition, CpG motifs in the DNA can be methylated or demethylated. 
When the CpG motifs are methylated, they are associated with chromatin-remodeling factors, 
such as methyl-DNA-binding proteins, resulting in chromatin condensation. The opposite 
occurs following demethylation of these motifs, which induces chromatin relaxation and an 
increased accessibility of specific transcription factors to target sequences. In mice and 
humans, distinct regions of Foxp3 and FOXP3 locus respectively have a pattern of DNA 
methylation and specific histone modifications that differ between Treg cells and conventional 
T cells. As previously described, sequence analysis have revealed three highly conserved non-
coding regions in FOXP3 locus, all of which have been found to be subject to epigenetic 
modifications and to be involved in regulating FOXP3 transcription. 
 
1.3.6. Post-translational modifications of FOXP3 
Post-translational modifications are essential for the expression, location, stability and 
function of many functional proteins, including histones, transcriptional factors and other 
cellular proteins. It is known that FOXP3 can be acetylated, phosphorylated, ubiquitinated, 
and proteolytically processed. Focusing on lysine residues conserved between mouse and 
humans in FKH domain, mutations of K383 and K393 have been found to significantly 
reduce the capacity of FOXP3 to suppress gene target expression, i.e. IL-2, and to confer 
suppressive ability to naïve CD4+ T cells (Tao et al., 2007; Liu et al., 2012). However, 
whether these lysines are the target of acetylation is was not clarified. Other three lysine 
residues, K31, K62 and K67 have been shown to be acetylated both in mouse and in humans 
by the histone acetyltransferase p300, recently identified for its ability to acetylate and 
stabilize Foxp3 protein (Kwon et al., 2012). This process can be reversed by the histone 
deacetylase SIRT1 (van Loosdregtand et al., 2010; van Loosdregtand et al., 2011). Prevention 
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of FOXP3 deacetylation by inhibition of SIRT1 decreased FOXP3 poly-ubiquitination and 
proteosomal degradation (van Loosdregtet al., 2011). These evidences suggested that 
acetylation of FOXP3 increases its stability and the suppressive function of Treg cells. 
FOXP3 can be also post-translationally modified and targeted for degradation in the presence 
of hypoxia-induced factor 1 (HIF1α), although more investigations are required to better 
understand the mechanism of this process (Dang et al., 2011). Likewise, the significance of 
FOXP3 phosphorilation is still very limited.  
 
1.3.7. FOXP3 and its interaction partners 
Chromatin immunoprecipitation, combined with microarray analyses, revealed 
numerous transcriptional targets of human and murine FOXP3, including genes whose 
expression is up-regulated (Cd25, Ctla4, Gitr) and repressed (Il2, Il4 and Ifnγ) (Zheng et al., 
2007). Several biochemical data indicate that FOXP3 does not function alone, but rather 
coordinates itself with various transcription factors, such as NFAT, NF-κB, AP-1 and 
AML1/Runx1, to mediate transcriptional regulation of target genes ( Chen et al., 2006; Wu et 
al., 2006; Bettelli et al., 2005; Ono et al., 2007). Among sequence-specific transcription 
factors serving as FOXP3-interaction partners, NFAT and Runx1 were proposed to be 
indispensable for establishing Treg cell transcriptional and functional programs (Wu et al., 
2006; Ono et al., 2007). The molecular details of NFAT-FOXP3 interactions were initially 
provided by crystallographic analysis of tertiary complexes of DNA and DNA-binding 
domains of NFAT and FOXP2, a close relative of FOXP3 (Wu et al., 2006), and subsequently 
of similar ternary complexes with the FOXP3 forkhead domain (Bandukwala et al., 2011). 
Interaction of FOXP3 with NFAT are thought to prevent formation of NFAT-AP1 complexes, 
required for the expression of immune response –promoting genes in effector T cells, thereby 
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ensuring their repression in Treg cells. NFAT-FOXP3 cooperation can drive the genomic 
program required for Treg cell differentiation and function (Wu et al., 2006). Indeed, site 
directed mutagenesis of predicted NFAT interaction sites in the DNA binding domain of the 
FOXP3 protein resulted in a loss of its ability to impose the Treg gene signature and 
suppressor function (Wu et al., 2006). Most investigations are focused on Runx1 since it is 
expressed in both Treg and T conv cells and regulates expression from the IL-2 and INF-γ 
promoters (Ono et al., 2007). A mutant form of FOXP3 unable to bind to Runx1 fails to 
suppress IL-2 production, demonstrating that interaction is critical for this function (Ono et 
al., 2007). The importance of Runx1 to Treg cell function is further illustrated by the fact that 
mouse CD4+ T cells transduced with a mutant FOXP3 that cannot bind to Runx1 are less 
suppressive that cells transduced with wild type FOXP3. Moreover, knockdown of Runx1 in 
human Treg cells attenuates their suppressive capacity (Ono et al., 2007). The interaction of 
FOXP3 with chromatin-modifying proteins, such as TIP60, HDACs 7 and 9, shows the 
mechanism used by this transcription factor to promote o repress target genes. An open 
chromatin structure is responsible for gene transcription through acetylation of histones 3 and 
4 on lysine residues and trimethylation of histones 3 at lysine 4 (H3K4me3). On the contrary, 
trimethylation of histones 3 at lysine 9, 27 and 20 (H3K9me3, H3K27me3, H3K20me3) 
marks closed chromatin and represses gene transcription. In regards to this, early studies 
demonstrated that while FOXP3 binding to promoters that it represses (i.e. IL-2, IL-4 and 
INF-γ) results in histones 3 at these promoters, promoters that it trans-activates (i.e. GITR, 
CD25, and CTLA-4) show increased histone acetylation.  
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1.4. Characteristics of human CD4+CD25+ FOXP3+ regulatory T cells 
As previously described, in mice Treg cells were initially identified based on the 
expression of CD25hi (Sakaguchi et al., 1995). However, different from the mouse, not all 
CD4+CD25+ T cells are not regulatory in human since CD25 can be up-regulated in activated 
T cells. Only ~1-2% of cells with the highest CD25 expression has been shown to be 
functionally suppressive and, therefore, can be considered “authentic” Treg cells (Baecher-
Allan et al., 2001; Allan et al., 2007). The discovery that the transcription factor FOXP3 was 
necessary for Treg cell development and function in an entire class of CD4+ T cells sharply 
focused the spotlight on these cells (Hori et al., 2003). However, the expression of FOXP3 
that is specifically expressed by Treg cells in mice, can be induced in naïve CD4+ T cells that 
are activated in vitro (Allan et al., 2007; Gavin et al., 2006). Thus, although Treg cells express 
FOXP3, all FOXP3+CD4+ T cells cannot be considered as suppressive in humans. In addition 
to CD25 and FOXP3, these Treg cells express several cell surface markers such as CTLA-4, 
GITR, CD39 and CD73, many of which are also expressed by activated CD4+ T effector cells, 
and are therefore non Treg- specific. So far, a number of additional markers have been 
described as putative characterising Treg cells Although they are not perfect, some, however, 
allow the identification of subsets of Treg cells which may have slightly different functions.  
       
1.4.1. Cytotoxic T-Lymphocyte Antigen- 4 (CTLA-4) and Glucorticoid-Induced TNF  
Receptor (GITR) 
CTLA-4 (CD152), a homolog of CD28, is up-regulated on naïve T cells after 
stimulation (cell surface levels of CTLA-4 remain limited due to the rapid endocytosis) and 
suppresses T cell activation upon binding its B7 ligand (Krummel and Allison, 1995). Treg 
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cells constitutively express CTLA-4 (in the naïve mouse, CD4+CD25+ cells are only CD4+ 
cells to express CTLA-4). The origin of its expression on Treg cells is not known. Whether 
CTLA-4 is required for Treg generation or intrinsic regulatory capacity remains unresolved. 
However, as the absence or blockade of CTLA-4 is associated with autoimmunity, the 
signaling through this pathway may be important for Treg suppression function (Takahashi et 
al., 2000; Read et al., 2000; Read et al., 2006). CTLA-4 up-regulation is also associated with 
enhanced Treg activity in inflammatory bowel disease models and is required in Ab-mediated 
therapies for promoting allograft survival (Londrigan et al., 2010). As CTLA-4 is also 
inducibly expressed on human CD4+CD25- T cells, it is not a reliable Treg marker. 
GITR is a member of the TNF receptor (TNFR) superfamily which is expressed on 
components of both innate and adaptive immune system, including NK and T cells. Its natural 
ligand, GITRL, is a member of the TNF superfamily and it is expressed on endothelial cells 
and APCs (in particular macrophages, DC, and B cells) (Nocentini and Riccardi, 2005). GITR 
acts as a T cell co-stimulatory molecule upon encounter with GITRL-expressing APC 
presenting cognate antigen, leading to T cell proliferation and cytokine secretion (Tone et al., 
2003; Ronchetti et al., 2004). Initial enthusiasm that GITR could be a Treg marker, based on 
its high expression in Treg cells, abrogation of Treg suppression by GITR neutralization 
(McHugh et al., 2002; Shimizu et al., 2002), and its induction upon Foxp3 trunsduction of 
CD4+CD25- T cells (Hori et al., 2003; Fontenot et al., 2003), collapsed following finding that 
this molecule can be expressed on non-regulatory CD4+ T cells upon activation (Hanabuchi et 
al., 2006). Furthermore, it has been shown that GITRhi CD4+CD25+ T cells are not 
suppressive (Shimizu et al., 2002) and that Treg cells from GITR knockout mice are still 
suppressive (Ronchetti et al., 2004). 
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1.4.2. IL-7 receptor α-chain (CD127) 
IL-7 is a member of a cytokine family which includes IL-2, IL-4, IL-9, IL-15 and IL-
21 whose receptor utilizes a common γ chain in association with a cytokine specific high 
affinity α chain, such as CD25 for IL2R and CD127 for IL7R. Although there is some 
redundancy between the functions of these cytokines (i.e., IL-2 and IL-15), IL-7 is critical for 
the development and survival of several blood cell types. Mice mutant for IL-7 or either 
components of its receptor, have major hematopoietic abnormalities and exhibit T cell 
negative (T-), B cell negative (B-), natural killer cell-negative (NK-) severe combined 
immunodeficiency (SCID) (Puel et al., 1998). In humans, loss-of-function mutations in IL-
7Rα gene have been found to cause T-B+NK+SCID. CD127 is constitutively expressed on 
naïve T cells, lost from the cell surface upon T cell activation and re-expressed by memory T 
cells ( Fuller et al., 2005; Boettler et al., 2006; Huster et al., 2004; Li et al., 2003).  Naïve T 
cell that exit thymus have low expression of IL-2R and IL-5R and they are critically 
dependent on IL-7 for survival. Recently, several groups showed that the lack of cell surface 
CD127 can be a useful alternative to CD25 for the delineation and purification of human Treg 
cells (Seddiki et al., 2006; Liu et al., 2006; Hartigan-O’Connor et al., 2007). Indeed, FOXP3 
expression and suppressive ability were enriched in CD4+ T cells expressing low levels of 
CD127 (Liu et al., 2006; Seddiki et al., 2006). This molecule is a direct FOXP3 target (Liu et 
al., 2006) and could reflect the mechanism of the inverse correlation between levels of CD127 
and FOXP3 (FOXP3 may regulate CD127 transcription following binding to its promoter). 
However, conventional CD4+ T cells tend to down-regulate CD127 expression after 
activation. Therefore, CD127 expression alone cannot accurately discriminate Treg cells from 
activated T cells ex vivo. In addition, the combined use of CD127 and CD25 to isolate Treg 
cells is comprised by the existence of a non-regulatory FOXP3-expressing CD4+ T cell 
population in the periphery in humans. This population, which expresses low levels of 
 46 
FOXP3, has low to intermediate CD127 expression but does not suppress effector T cells in 
vitro and produces pro-inflammatory cytokines, including IL-2, IL-17, and IFN-γ (Miyara et 
al., 2009).  
 
1.4.3. CD39 and CD73 
Both CD39 and CD73 are ectoenzymes, called ectonucleoside triphosphate  
diphosphohydrolase-1 (ENTDP1) and 5′-nucleotidase, ecto (NT5E) respectively. The former 
dephosphorylates extracellular ATP/UTP to ADP/UDP and ADP/UDP to AMP/ UMP 
(Borsellino et al., 2007), while the latter converts the 5′-monophosphonucleotides into the 
dephosphorylated nucleotides (adenosine and uridine). In the immune system, extracellular 
ATP is an indicator of tissue destruction and its concentration is so high that substantial 
amounts of the nucleotide are released upon cell damage. CD39 and CD73 are expressed by B 
cells, DCs, all mouse Treg cells, and about 50% of human Treg cells. A complete degradation 
of 5′-triophosphorilated nucleotides to pericellular adenosine mediates T cell suppression 
through engagement of adenosine receptors (Huang et al., 1997). CD39 may be, therefore, a 
specific marker of Treg cells (Borsellino et al., 2007). In particular, this molecule is 
predominantly expressed on CD25hi Treg cells (Deaglio et al., 2007). CD39 more reliably 
identifies Foxp3-expressing T cells than CD25, both on a genetic association and on a protein 
expression level. Removal of extracellular ATP by CD39 may allow Treg cells to enter 
inflamed regions and permit them to quench ATP-driven pro-inflammatory processes on 
multiple cell types, particularly DCs. CD39-deficient Treg cells are dysfunctional because 
they are not anergic and proliferate in response to anti-CD3 and anti-CD28 stimulation in the 
absence of exogenous IL-2. Moreover, Treg cells from CD39null mice have markedly reduced 
ability to suppress CD4+CD25- proliferation, fail to prevent allograft rejection and develop 
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spontaneous autoimmune alopecia. This evidence suggests that hydrolysis of ATP and 
generation of adenosine via CD39 and CD73 represents an important mechanism of 
immunoregulation Treg-mediated (Bopp et al., 2007).  
` 
1.4.4. Galectins  
Galectin are lectins which bind β-galactoside. Using transcriptomic and proteomic 
assays to identify Treg-markers, two separate groups described expression of members of the 
galectin family on Treg cells .Galectin-1 is expressed by Treg cells at baseline and upon TCR 
engagement in both mice and humans. (Garin et al., 2007). Galectin-10 was also identified as 
constitutively expressed by Treg cells (Kubach et al., 2007). Antibodies blocking this 
molecule also abrogated Treg suppression in vitro. Interestingly, Treg cells from galectin-1 
knockout animals are numerically normal but functionally less suppressive than their wild-
type counterparts. 
 
1.4.5. Other Treg markers 
A series of other Treg-associated surface markers have also bee described in the 
literature. They have not been adequately validated and generally identify sub-population of 
Treg cells as opposed to being quintessential Treg markers in their own right. Of note, HLA-
DR is expressed on a subpopulation of Treg cells which account for approximately 20-30% of 
human CD4+CD25hi T cells (Baecher-Allan et al., 2001). HLA-DR+ CD4+CD25hi T cells 
suppress via an obligate contact-dependent mechanism which contrasts them from their HLA-
DR- CD4+CD25hi counterparts whose suppressive mechanism also includes the ability to 
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secrete an inhibitory soluble factor, IL-10 (Baecher-Allan et al., 2006). However, these Treg 
populations suppress both proliferation and cytokine production by target T cells. The 
inducible T cell co-stimulator ICOS (CD278) has been described on a subpopulation of both 
thymic and peripheral FOXP3+ cells (Ito et al., 2008). ICOS is a member of the CD28 and 
CTLA-4 family of co-stimulatory molecules and it is expressed on the surface of activated T 
cells where it forms homodimers upon engagement of its ligand, (ICOSL, CD275) playing an 
import role in cell-cell signaling and immune responses (Sperling and Bluestone, 2001; Dong 
et al., 2001; Coyle et al., 2000). The expression of ICOS on human Treg cells seems to direct 
these cells toward different cytokine profiles as CD4+CD25+ICOS+ T cells that produce both 
IL-10 and TGF-β, whereas CD4+CD25+ICOS - T cells produce only TGF-β (Ito et al., 2008). 
ICOS-expressing Treg cells, therefore, can suppress via contact-independent mechanism. This 
difference could be due to preferential signaling through ICOS and CD28 respectively 
(Yoshinaga et al., 1999; .Hutloff et al., 1999) 
Other markers described in association with Treg phenotype include: Neuropilin-1 
(Nrp-1), a multi-functional protein able to bind class 3 semaphorin proteins and vascular 
endothelial growth factor (VEGF) family members, which could either activate TGF-β from 
its latent form on Treg cells or prolong interactions between Treg cells and DCs; the 
cytotoxicity-associated proteins Perforin and Granzymes A and B which are thought to help 
suppression through direct death of target cells. 
 
1.5. Thymic and peripheral origins of Treg cells 
Similar to all other T cells, Treg cells originate from progenitor cells in bone marrow 
and undergo lineage commitment in the thymus. A thymic origin for Treg cells was suggested 
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by the neonatal thymectomy–induced autoimmunity models described above (Sakaguchi et 
al., 1995). In addition, adoptive transfer of Treg cells from donor animals lacking ovaries, 
testes, prostate or thyroid glands did not inhibit organ-specific autoimmunity diseases caused 
by neonatal thymectomy suggesting an antigen- specific imprinting on Treg cells during 
thymic education. Thymic development of Treg cells requires high-affinity interactions 
between their T cell receptor (TCR) and self-peptide-MHC complexes presented by thymic 
stromal cells (Hinterberger et al., 2010). These cells also provide co-stimulatory signals 
required for Treg cell lineage development as shown by the decrease in the number of Treg 
cells generated in the thymus following loss of CD40 or CD28 expression. (Salomon et al., 
2000; Tai et al., 2005). Other signals that are necessary for Treg cells differentiation include 
IL-2 and, to a lesser degree, two other cytokines, IL-7 and IL-15 acting through the common 
gamma-chain (γc) cytokine receptors .Mice deficient in IL-2 or CD25 showed a 50% decrease 
in the proportion and absolute numbers of Foxp3+cells, whereas loss of IL-7 or IL-15 did not 
perturb generation of Foxp3+ cells (Vang et al., 2008; Fontenot et al., 2005; Burchill et al., 
2007). Based on the role for IL-2 and TCR signaling strength, it has been proposed a “two-
step model” for thymic Treg cell differentiation: high functional avidity TCR signals result in 
CD25 up-regulation and a subsequent increase responsiveness of Treg precusors to IL-2 
signals facilitate Foxp3 induction (Burchill et al., 2008; Lio and Hsieh, 2008). Given the 
known similarities between mouse and human thymocyte development, it is likely that many 
of these requirements for Treg cells in mice are similar for human Treg cell development. The 
peripheral pool of Treg cells not only includes those differentiated in the thymus but also Treg 
cells generated extra-thymically through the “conversion”of naïve precursors in the periphery. 
The conditions favouring peripheral induction of Treg (iTreg) cells include suboptimal DC 
activation, presence of appropriate cytokines and subimmunogenic doses of agonist peptide 
(Gottschalk et al., 2010). Two main subsets of iTreg cells have been described based on the 
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cytokines they produce and that cause their induction: type 1 regulatory T cells (Tr1), which 
are induced by IL-10 (Vieira et al., 2004), and T helper 3 (Th3) cells, which are induced by 
TGF-β (Weiner, 2001). Both subsets exert their suppressive activity trough secretion of the 
same cytokines that are responsible for their induction, IL-10 and TGF-β respectively. Since 
there are not phenotypic markers to distinguish peripherally-induced (iTreg) from thymically-
derived natural Treg cells (nTreg) (molecular differences at the level of epigenetics can 
distinguish them), the question remains as to whether nTreg and iTreg cells have overlapping 
or distinct functions. The finding that the requirements for the induction of Foxp3 in the 
thymus and periphery are distinct, suggests that the function of these two Treg cell subsets, 
nTreg and iTreg cells, are also distinct. iTreg cells are thought to be an important population 
in the gut mucosa to maintain tolerance to commensal flora and food antigens (Lathrop et al., 
2011). In several other physiological setting, these cells are also found, including transplanted 
tissue allografts, within the tumor microenvironment and chronic inflammatory sites. In all 
these cases, iTreg cells are thought to be antigen-specific and mediate beneficial effects 
limiting tissue rejection and inflammation. 
 
1.6. Regulatory T cell and immune-suppression 
Treg cells are described as “anergic” due to their poor proliferation in response to TCR 
ligation in the context of appropriate co-stimulation and, once activated, they can inhibit T 
cells irrespective for their antigen specificity. Unlike conventional CD4+CD25- T cells, they 
do not produce IL-2 upon activation. This is the result of proximal block in the TCR signaling 
that leads to defective receptor-mediated calcium flux and phosphorylation of extracellular 
signal-regulated kinase (ERK). There are suggestions that the proximal block may be due to 
impaired CD3ζ chain phosphorylation in response to TCR ligation, although the reasons for 
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this are unknown (Tsang et al., 2006). However, Treg cells have an obligate requirement for 
TCR activation in order to function and can be induced to proliferate in the presence of 
exogenous IL-2. In vitro, Treg cells have the ability to inhibit proliferation and production of 
cytokines (i.e. IL-2 and IFN-γ) by responder T cells (CD4+CD25- and CD8+) to polyclonal 
stimuli, as well to down-modulate the responses of CD8+ T cells, NK cells and CD4+T cells to 
specific antigens. Several mechanisms have been proposed for Treg-mediated suppression 
including (i) cell contact mediated mechanism; (ii) cytokine mediated mechanism; (iii) 
cytotoxicity (Sakaguchi et al., 2008; von Boehmer and 2005; Shevach , 2009). 
 
1.6.1. Cell- contact mediated mechanism (i) 
Cell-contact dependent mechanism of suppression is based on the evidence that 
suppression can be abrogated via separation of Treg and effector T cells by a semi-permeable 
membrane and that TCR signaling is critical to their function (Takahashi et al., 1998). A 
number of mechanisms for Treg cell-mediated suppression in vitro has been proposed that 
appear to primarily affect the function of APCs (Tadokoro et al., 2006). Human Treg cells are 
the only lymphocyte sub-population that constitutively expresses CTLA-4. This notion has 
raised the possibility that the interaction of CTLA-4 on Treg cells with CD80 and CD86 on 
DCs is an important pathway for Treg suppressive function in vitro. As previously mentioned, 
selective deletion of CTLA-4 expression provokes systemic autoimmunity. Thus, CTLA-4 
deficiency in Treg cells alone is sufficient to cause fatal disease (Wing et al., 2008) and 
maintenance of its expression in activated effector T cells is insufficient to prevent this 
outcome. There are various mechanisms by which CTLA-4 exerts its role in Treg mediated 
suppression. CTLA-4 binds to CD80 and CD86 on APCs and down-regulates expression of 
these B7 molecules (Misra et al., 2004; Serra et al., 2003), hampering their capacity to 
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stimulate naïve T cells through CD28 (Onishi et al., 2008; Wing et al., 2008). CTLA-4 up-
regulates the expression of lymphocyte function associated antigen 1 (LFA-1) thereby 
augmenting the physical interaction between Treg cells and APCs (Schneider et al., 2005). 
Moreover, ligation of CTLA-4 on Treg cells with CD80 and/or CD86 on DCs could induce 
the production of the enzyme indolamine 2,3 dioxygenase (IDO) in DCs. IDO catalyzes the 
conversion of tryptophan into pro-apoptotic metabolites that result in the suppression of 
effector T cell activation (Fallarino et al., 2003). However, there is no clear evidence about 
the involvement of IDO in Treg function in vitro or in vivo. It was claimed that Treg cell-
mediated suppression of proliferation could be reversed by anti-CTLA-4 or its Fab fragment 
in vitro (Thorton et al., 2004). Although very few studies have examined the effects of anti-
CTLA-4 in vivo, it has been shown that treatment of mice with anti-CTLA-4 abrogates the 
suppression of IBD mediated by Treg cells (Read et al., 2006). Another cell surface antigen, 
that may play a role in Treg cell suppression of DC function, is lymphocyte-activation gene 3 
(LAG-3, CD233), a CD4 homolog that binds MHC class II molecules with high affinity. 
Binding of LAG-3 to MHC II molecules expressed by immature DCs induces ITAM-
mediated inhibitory signal that suppress DC maturation and immunostimulatory capacity 
(Liang et al., 2008). Because activated human T cells can express MHC class II, Treg cell-
mediated ligation of LAG-3 on effectors might also result in suppression.  
 
1.6.2. Cytokine- mediated mechanism (ii) 
Although cell contact is required for in vitro Treg -mediated suppression, several data 
in vivo show an important role of inhibitory cytokines, like IL-10 and TGF-β, as mediators of 
Treg activity (Nakamura et al., 2001; Maynard et al., 2007) Treg cells isolated from IL-10 
knockout mice failed to prevent colitis and homeostatic proliferation of CD4+ T cells from 
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Rag deficient mice (Annacker et al., 2001). Moreover, blockade of IL-10 receptor and 
neutralization of TGF-β abolished Treg mediated inhibition of the disease. This evidence 
suggests that IL-10 production by Treg cells is essential for keeping the immune response in 
check at environmental interfaces such as colon and lungs (Rubtosov et al., 2008). It also 
been shown that tumor microenvironment promotes the generation of Tr1 cells which mediate 
IL-10 dependent immune suppression in a cell contact independent manner. Similarly, another 
immunosuppressive cytokine secreted by Treg cells, TGF-β, has been suggested to contribute 
to suppressive activity of these cells. Although stimulated Treg cells express high and 
persistent levels of TGF-β on their cell surface, the role of this cytokine as a suppressor 
effector molecule remains controversial. Nakamura et al. first raised the possibility that TGF-
β produced by Treg cells is bound to the cell surface, by an unknown receptor, and would 
mediate suppression in a cell contact-dependent fashion (Nakamura et al., 2001). In their 
studies this suppression could be reversed by high concentrations of anti-TGF-β. So, they 
postulated that latent TGF-β, bound to the cell surface of activated Treg cells, is delivered 
directly to responder T cells and is then locally converted to its active form. It has also 
recently demonstrated that the major role of the expression of latent TGF-β on the surface of 
murine Treg cells is to convert Foxp3- T cells into Foxp3+ Treg cells by a mechanism of 
infectious tolerance when both populations are activated via their TCRs in a DC-independent 
manner (Andersson et al., 2008). However, the contribution of TGF-β to suppressive capacity 
of Treg cells in vivo remains controversial. A number of in vivo experiments have 
demonstrated that autocrine production of TGF-β by Treg cells is not essential for their 
suppressive function. For example, Treg cells from Tgfb1-/- mice or from mice expressing a 
dominant-negative form of TGF-βRII were able to inhibit IBD induced by Foxp3- T cells in 
vivo (Fahlen et al., 2005). In contrast, mice with a T-cell specific deletion of TGF-β 
production developed an autoimmune syndrome including IBD (Li et al., 2007). The 
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differences between these studies are unclear, but may relate to the flora in different animal 
colonies.  
Recently, a new inhibitory cytokine, IL-35, has been shown to be preferentially expressed on 
Treg cells and contribute substantially to Treg function by directly acting on responder T cells 
(Collison et al., 2007). IL-35 is a member of the IL-12 heterodimeric cytokine family and 
constitutes a pairing between Epstein-Barr virus induced gene3 (Ebi3) and Il-12a. Both Ebi3 
and Il-12a mRNA are up-regulated in Treg cells that are actively suppressing effector cells, 
raising the possibility that cell contact between Treg and T responder cells is required for 
maximal IL-35 production. Importantly, both Ebi3-/- and Il12a-/- Treg cells have substantially 
reduced regulatory activity in vitro. Treg cells from Ebi3-/- and Il12a-/- animals also were 
unable to control homeostatic proliferation and cure IBD (Collison et al., 2007) in vivo. 
Neutralizing antibodies to IL-35 are not available and the nature of its receptor or its cellular 
distribution remains unknown. 
 
1.6.3. Cytotoxicity (iii) 
One other potential mechanism for Treg-mediated suppression of responder T cells is 
cytolysis of target cells. Activated Treg cells have been shown to express granzyme A and kill 
target cells in a perforin–dependent, Fas-FasL independent manner (Grossman et al., 2004). 
Activation of murine Treg cells also results in up-regulation of granzyme B expression. 
Recent report has claimed that Treg cells kill responder cells by a perforin-independent, 
granzyme B-dependent mechanisms (Gondek et al., 2005) and that granzyme B-deficient 
Treg cells had reduced suppressive activity in vitro. It has been difficult to demonstrate 
granzyme B expression by Treg cells in vivo. However, Cao et al. demonstrated that 5%-30% 
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of Treg cells in a tumor micro-environment express granzyme B and these Treg cells are lytic 
for NK and CTL cells in a granzyme B- and perforin-dependent manner (Cao et al., 2007). 
Thus, Treg cells in certain contexts can differentiate to become what one termed “cytotoxic-
suppressor” cells. Although killing of APCs in vivo represents a potentially potent mechanism 
by which Treg cells can control both primary and secondary immune responses, no studies to 
date have been able to document Treg cell-mediated cytolysis of DC or B cells in a model in 
vivo. Human Treg cells have been shown to express Fas and FasL in co-cultures containing 
Treg and responder T cells and activated Treg cells induced Fas- mediated apoptosis in 
autologous CD8+ cells (Strauss et al., 2009). Activated Treg cells could also induce apoptosis 
of conventional T cells through a tumor necrosis factor related apoptosis inducing ligand-
death receptor 5 (TRAIL-DR5) pathway (Ren et al., 2007). Also galectin-1, which can induce 
cell cycle arrest and/or apoptosis in T cells, has been shown to be up-regulated by Treg cells 
upon activation and galectin-1 deficient Treg cells have reduced regulatory function in vitro 
(Garin et al., 2008). 
Thus, various in vivo and in vitro studies suggest several molecules and mechanisms 
may operate in Treg mediated suppression. One question that arises is how such multiple 
modes of suppression interact which each other in maintaining immune homeostasis. It is 
possible that a particular mechanism may play a dominant role under a particular condition, 
with different mechanism operating in various situations, depending on the local micro- 
environment in which Treg cells act. Therefore, Treg-mediated or dependent suppressive 
mechanisms can be categorised into two classes. One is Treg-dependent deprivation of 
activation signals from responder T cells to keep them in a naïve state; the other is direct 
intervention by Treg-mediated killing and inactivation of T responder cells and APCs. The 
former serves in physiological and non-inflammatory states and is responsible for sustaining 
natural self-tolerance, while the latter acts in inflammatory conditions and maintains immune 
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homeostasis at local sites (i.e., intestinal mucosa) constantly exposed to invading microbes. 
 
1.7. Maintenance of steady state immune homeostasis 
Given that activation, proliferation, and survival of antigen-reactive conventional T 
cells require several kinds of co-stimuli in addition to antigenic stimulation via TCR, Treg-
dependent deprivation or intervention of such co-stimuli can attenuate or suppress immune 
responses. The deprivation mechanism include: inhibition of CD28 signals (by LFA-1 
dependent out-competition of Treg cells over naïve T cells for physical interaction with APCs 
and by CTLA-4 dependent down-regulation of CD80/CD86 expression on APCs); IL-2 
deprivation via CD25 expressed by Treg cells and CD39/CD73-dependent degradation of 
ATP. In the absence of Treg cells, naïve T cells can repetitively interact with APCs receiving 
undisturbed CD28, IL-2 and ATP stimuli. This deprivation mechanism controls the survival 
and function of Treg cells via a negative feedback loop. Since Treg cells themselves are 
unable to produce IL-2, they are dependent on IL-2 produced by activated conventional T 
cells. In addition, Treg cells require CD28 signaling for their own peripheral maintenance 
(Garbi and Hammerling, 2011). Thus, by suppressing conventional T cells activation and APC 
CD80/CD86 expression, Treg cells also control their own numbers, preventing their excess 
and ensuring that immune system is still able to mount an effective immune response if 
challenged. Interruption of this feedback loop at any step may affect immune homeostasis. 
For effective host defense, however, Treg-mediated suppression should be transiently 
abrogated when pathogens invade the host. There are many demonstrations that TCR, in the 
presence of strong co-stimulation via CD28 and/or high concentrations of IL-2, enables 
responder T cells to overcome the suppression by Treg cells (Takahashi et al., 1998; Thornton 
and Schevach, 1998). This temporary abrogation of Treg-mediated suppression allows the 
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immune system to respond to pathogens affectively. 
 
While a temporary attenuation of suppression is required for mounting an effective immune 
response, Treg cells must regain control in high inflammatory conditions in order to prevent 
immuno-pathology, i.e., tissue-damaging excessive immune responses. In these conditions, 
the deprivation mechanisms, physiologically in operation, are abrogated by abundant co-
stimulation. Therefore, Treg cells produce immuno-suppressive molecules to directly and 
potently suppress responder T cell activation and proliferation. That is, besides the core 
mechanism of suppression, cytotoxic or inactivating mechanisms additionally operate to 
suppress activated conventional T cells by IL-10, TGF-β, granzyme and perforin. Treg cells 
amplify their expansion and suppressive capacity in a positive feedback loop inducing the 
differentiation of conventional T cells into T cells secreting respective suppressive cytokines, 
to effectively contain excessive inflammation. Thus, Treg-mediated suppression mechanisms 
can be separated in two modes or phases, differentially utilized in non-inflammatory and 
inflammatory conditions. Exceedance or attenuation of each mode dynamically controls the 
intensity of immune responses while avoiding collateral tissue damage and sustaining self-
tolerance.  
 
1.8. Stability of human CD4+CD25+FOXP3+ Treg cells 
FOXP3+ Treg cells have been initially viewed as a stable cell lineage highly 
specialized and fully committed to suppress effector T cells. Therefore, Treg function must be 
remarkably durable and stable under homeostatic conditions, particularly in evolving 
inflammatory microenvironments. Recently, the concept that Foxp3+ Treg cells are 
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irreversible in their lineage has aroused considerable controversy. Initial studies in mouse 
showed that up to 20 % of Treg cells could lose Foxp3 expression, particularly at sites of 
inflammation (Zhou et al., 2009). However, two subsequent studies argued that fully 
committed nTreg cells are remarkably stable, and that any apparent instability could be related 
to the presence of a small fraction of un-committed Treg cells or iTreg cells less stable than 
nTreg cells (Miyao et al., 2012; Rubtsov et al., 2010). In humans, single cell cloning has been 
used to study the stability of FOXP3 expression (d’Hennezel et al., 2012). Like previous 
studies in mice, significant heterogeneity was observed in Treg pool, with some cells losing 
FOXP3 expression and suppressive capacity (Hansmann et al., 2012). These data also called 
into question the therapeutic applicability of iTreg cells in humans, as these cells are less 
likely to remain FOXP3+ when transferred in vivo (Hippen et al., 2011). So, considering the 
indispensable and lifelong role of FOXP3 in Treg activity (Allan et al., 2007), studies on Treg 
stability have used FOXP3 expression as a marker for functional Treg cells. Over the last 
years, many groups have sought to find ways to stabilize the expression of this transcriptional 
factor. As previously described in the section 1.3.2., epigenetic modifications of the FOXP3 
locus have a major role in controlling FOXP3 transcription (Floess et al., 2007). In particular, 
the degree of demethylation of Foxp3 locus TSDR ensures durable and stable FOXP3 
expression resulting in suppressive function of Treg cell population. Whereas nTreg cells are 
demethylated at this specific region, iTreg cells present an intermediated level of methylation 
similar to that of effector T cells ( Baron et al., 2007; Floess  et al., 2007; Polansky et al., 
2008). This variation could be one of the reasons for the instability of iTreg cells and, 
therefore, the paucity of these cells in vivo in transplant rejection, even under tolerizing 
conditions. FOXP3 expression, although instrumental to the development of Treg cells, is not 
an on- and-off switch to Treg cell functionality. In fact, different levels of this marker 
influence Treg suppressive activity and, reduced levels of FOXP3 expression result in an 
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impaired function of these cells. A number of studies coming from the mouse models 
demonstrated that Treg cells can lose Foxp3 expression in response to specific stimuli. 
Inflammatory cytokines such as IL-4, IL-6 and IL-21 have been shown to down-regulate 
Foxp3 expression in vitro and contribute to Treg reprogramming in vivo (Jin et al., 2008, Park 
et al., 2005; Tsuji et al., 2009; Zhou et al., 2009). By contrast, anti-inflammatory cytokines, 
such as IL-10, can stabilize Foxp3 expression in both nTreg and iTreg cells, as Treg cells 
deficient in IL-10 signaling lose Foxp3 expression (Kuhn et al., 1993; Rubtossov et al., 
2008). In humans, CD4+CD25low T cells that express low levels of FOXP3 can readily lose its 
expression and acquire IL-17-producing ability (Radhakrishnan  et al., 2008) Recent evidence 
by Bluestone et al. showed that a notable fraction of nTreg cells failed to maintain FOXP3 
expression. Such “ex-Treg cells” produce IFN-γ and mediate the development of autoimmune 
diabetes. Treg cell pool, therefore, seems to contain uncommitted Treg cells that are likely 
predisposed to lose FOXP3 expression and become effector T cells (Zhou et al., 2009). 
However, Treg cells exhibiting unstable FOXP3 expression do not necessarily acquire 
effector-like T cell properties. The reasons of this functional re-programming are unknown 
but could reflect the heterogeneity among human Treg cells.  
 
1.9. Heterogeneity of human FOXP3+ Treg cells 
As described in the previous section, Treg cells are a heterogeneous pool and only a 
committed population maintains long-term stable FOXP3 expression and suppression ability 
in vitro. Supporting this hypothesis, Miyara et al recently identified three phenotypically and 
functionally separate populations based on the expression of FOXP3 and CD45RA, namely 
naïve o resting FOXP3low CD45RA+ Treg cells (P1, nTreg cells), effector or activated 
FOXP3hi CD45RA- Treg cells (P2, eTreg cells) and cytokine-secreting FOXP3lowCD45RA- 
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non suppressive Treg cells (P3, non Treg cells). As the expression levels of FOXP3 are 
proportional to those CD25, eTreg cells (P2) can be defined as CD45RA-CD4+ T cells with 
the highest expression of CD25. This subset can be distinguished from the other CD4+ T cells 
populations because P2 has an expression of CD25 higher than naïve Treg cells (P1) (Miyara 
et al., 2009). So, FOXP3+ Treg cells can be separated according their levels of CD25 and 
CD45RA only and the analysis of CD127 expression is not indispensable to isolate Treg cells.  
                              
                         Adapted from Miyara et al. Autoimmunity Reviews, 2011 
 
Although these cells express FOXP3, are not all suppressive. The difference between non 
Treg cells (P3) and functional Treg cells (P1 and P2) may be linked to the methylation status 
of the FOXP3 gene, which is incompletely demethylated in P3 subset but is completely 
demethylated in both P1 and P2 subpopulations with suppressive activity. The observation 
that in patients with active lupus erythematosus CD4+CD25hiCD45RA- T cells are highly 
expanded (Lin et al., 2007; Bonelli et al., 2008; Zhang et al., 2008; Venigalla et al., 2008; Yan 
et al., 2008) is an indirect evidence for their non-suppressive status in vivo. These findings 
P2 
P1 
P3 
(P1) 
(P2) 
(P3) 
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indicate that human FOXP3+Treg subsets are distinct and might behave differently in vivo and 
in vitro. 
 
1.9.1. FOXP3low CD45RA+ Treg cells (P1) 
Naïve Treg cells are characterized by their surface expression of CD45RA and their 
low levels of intra-nuclear FOXP3 (Miyara et al., 2009; Ito et al., 2008; Fritzsching et al., 
2006). CD45RA is a phenotypic marker for naïve T cells that have no experienced TCR 
simulation. However, based on mouse data, Treg cells need to be stimulated continuously by 
their cognate antigen to be maintained in the periphery (Fisson et al., 2003). Therefore, 
although they express CD45RA, these Treg cells cannot be considered strictly naïve T cells 
(Miyara et al., 2009; Ito et al., 2008; Fritzsching et al., 2006). Naive Treg (P1) cells 
proliferate in vitro after TCR stimulation and are highly resistant to apoptosis (Miyara et al., 
2009). On the contrary, FOXP3hiCD45RA- Treg cells (P2) tend to be hyporesponsive and 
apoptotic in the same conditions. Once activated, naïve Treg cells proliferate, up-regulate 
FOXP3 expression and convert to CD45RA-CD25hiFOXP3hi Treg cells. This evidence 
suggests that the human counterpart of mouse thymus-derived nTreg cells is more likely to be 
the P1 population rather than P3 subset (Miyara et al., 2009; Fritzsching et al., 2006). 
 
1.9.2. FOXP3hi CD45RA- Treg cells (P2) 
As previously mentioned, FOXP3hi CD45RA- Treg cells Treg cells, which seem to 
derive mainly from FOXP3low CD45RA+ Treg subset, have potent suppressive activity and 
show hypo- responsiveness and high susceptibility to apoptosis following activation in vitro 
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(Baecher-Allan et al., 2001; Dieckmann et al., 2001). In contrast to P1 subset that is in a 
resting state, CD45RA-FOXP3hi Treg cells can be thought to be an activated and functionally 
differentiated population of Treg cells. However, these cells need to be further stimulated 
through their TCR to exert suppression in vitro (Baecher-Allan et al., 2001; Levings et al., 
2001; Jonuleit et al., 2001). Based on these findings, CD45RA- FOXP3hi Treg cells are called 
“effector Treg cell”. They are more prevalent in adults and elderly people (Miyara et al., 
2009) vs nTreg cells which are enriched in cord blood. Although eTreg cells express 
CD45RO, a marker of conventional memory T cells, there is no evidence of memory and 
recall responses by Treg cells in mouse experiments. Indeed, these cells undergo rapid 
turnover, which is not indicative of a long-lived memory T cell population (Vukmanovic et 
al., 2001). However, the possibility remains that effector Treg cells may mature to become 
terminally differentiated suppressor cells that rapidly succumb to cell death.   
 
1.9.3. FOXP3lowCD45RA- non suppressive Treg cells (P3) 
These non suppressive T cells that display low expression of FOXP3, may correspond 
to recently activation-induced FOXP3-expressing cells that transiently express FOXP3 in 
vitro (Allan et al., 2007; Gavin et al., 2006; Tran et al., 2007; Wang et al., 2007). Indeed, 
although the 5’ flanking region of FOXP3 gene in this Treg subset is highly demethylated, the 
STAT5-responsive region is poorly demethylated, suggesting that FOXP3lowCD45RA- Treg 
cells could be unstable in maintaining FOXP3 expression through STAT5 signaling. 
Moreover, recent evidence showed that activation-induced FOXP3+CD4+ T cells have FOXP3 
gene significantly less demethylated than both P1 and P2 subpopulations (Baron et al., 2007; 
Janson et al., 2008) and they can produce IFN-γ and/or IL-17 (Miyara et al., 2009). 
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1.10. Treg cells as cell therapy 
The biology of Treg cells has been the subject of much recent interest, in particular 
with regards to induction of transplantation tolerance. This condition can be defined as a state 
of unresponsiveness of an immune response to an inflammatory situation such as that 
generated by the recipient immune response following transplantation (Sagoo et al., 2012). 
Although the primary function of Treg cells is the maintenance of tolerance to self 
components to prevent development of autoimmune diseases, the presence of Treg cells in 
tolerated allograft suggests that they play a role in the persistence of transplanted organs. 
Therapeutic infusion of Treg cells has the potential to induce long-term donor specific 
tolerance without impeding desired immune responses to pathogens and tumors in transplant 
patients. Research in animal models has demonstrated that Treg cells can be used to treat 
many auto-inflammatory diseases such as type 1 diabetes (T1DM), inflammatory bowel 
disease (IBM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple 
sclerosis (MS) and autoimmune gastritis (AG). In addition, Treg therapies have been found to 
be efficacious in controlling allo-immune responses in settings of graft-versus-host disease 
(GvHD) as well as organ and cell transplantation in animal models (Trzonkowski et al., 2009; 
Brunstein et al., 2010; Di Ianni et al., 2011). However, given the small number of Treg cells 
in peripheral circulation, it is necessary to optimize methods to expand these cells in vitro. 
Therefore, one of the major goals in Treg therapy is to maintain the purity and suppressive 
ability of Treg preparation after in vitro expansion and to limit the potential to produce pro-
inflammatory cytokines, such as IL-17, particularly when Treg cells are exposed to an 
inflammatory environment in vivo (d’Hennenzel et al., 2012; Hamann et al., 2012). Both 
these limitations may be in part due to the presence of “contaminating” effector T cells within 
bead-separated Treg preparations. This is not surprising as the culture conditions also favor 
proliferation of CD25+effector T cells, which may contaminate the purified starting 
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population and outgrowth in culture (Hoffmann et al., 2009). Nevertheless, as described 
earlier, human Treg cells can lose their suppressive capability and convert into IL-17-
producing T cells. The ability to expand ex vivo Treg cells, while maintaining 
immunoregulatory function, makes them particularly suitable for adoptive cell therapy to 
establish clinical transplantation tolerance. 
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2. Part I: Role of Forkhead Trascription Factor P3 (FOXP3) on 
Cd25 gene trans-activation 
 
2.1. Introduction  
The central role of FOXP3 in Treg cell identity and function raised the question 
regarding how much FOXP3 directely affects the transcriptional signature of Treg cells. A 
direct investigation of the contribution of FOXP3 to transcriptional and functional features of 
Treg cells was made possible through the analysis of mice harboring a Foxp3 reporter null 
allele (Foxp3GFPKO) (Gavin et al., 2007) or a truncated version of the Foxp3 protein lacking 
DNA-binding domain tagged with GFP (Foxp3ΔeGFP) (Lin et al., 2007). Cells expressing 
these alleles exhibited some of the phenotypic and molecular characteristics of Foxp3+Treg 
cells including an inability to proliferate and produce IL-2 in response to TCR stimulation, 
expression of low amounts of IL-7α chain (CD127) and elevated amounts of CD25, CTLA-4 
and GITR, although at significantly lower levels compared with Treg cells. In addition, 
FOXP3 amplifies and stabilizes the expression of a number of genes transiently up-regulated 
in activated non-regulatory T cells. Many products of these FOXP3-dependent amplified or 
stabilized genes in Treg cells (such as CTLA-4 and  IL-10) act in a cell-intrinsec manner to 
limit activation of conventional T cells and serve as negative feedback regulators. FOXP3 
enforces repression of the immune promoting-genes normally induced in naïve and effectotr T 
cells upon TCR stimulation. Thus, the analysis of the FOXP3-dependent trancriptional 
program invites the question of how many genes are directly regulated by FOXP3. As 
previously mentioned,  in contrast to the early notion that FOXP3 acts as a trascriptional 
repressor (Bettelli et al., 2005; Schubert et al., 2001; Lopes et al., 2006 ), more FOXP3-bound 
genes are up-regulated than repressed in Treg cells. Moreover, the finding that retrovirus-
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mediated over-expression of FOXP3 in naive CD4+ T cells from mice is sufficient to 
recapitulate all of the known features of Treg cells, including suppression of autoimmunity 
and rejection of transplanted grafts in vivo, (Hori et al., 2003; Fontenot et al., 2003) led to a 
better investigation of how FOXP3 mediates its functions at molecular level. A more thorough 
understanding of the molecular mechanisms by which FOXP3 activates and represses gene 
transcription would also be useful for development of therapies to interfere with or enhance 
these processes. 
 
2.2. Research goal 
The high expression of IL-2Rα (CD25) on CD4+CD25+FOXP3+ regulatory T cells, 
suggests that Treg cells are more dependent on IL-2 for survival and function than 
CD4+CD25- T cells. This evidence has stimulated intense research aimed to understand the 
mechanisms by which FOXP3 regulates transcription of Il2 and several other genes. Although 
research carried out over the last years has widely clarified the repressive activity of FOXP3 
(Chen et al., 2006), it is still unclear how this transcriptional factor positively can regulate 
other genes, like Cd25 and Ctla4. Since considerable evidence supports the prediction that 
CD25 expression is directly regulated by FOXP3 (Hori et al., 2003), the goal of this chapter 
was to examine the functional responsiveness of the Cd25 promoter to FOXP3. To this aim a 
CD25 promoter-luciferase construct has been prepared to clarify the FOXP3 trans activatory 
function. It has been also investigated whether the effect of FOXP3 on CD25 transcription 
required a coordinated interaction with NF-κB that it has been identified as the main activator 
of CD25 expression. However, while the role of NF-κB in Cd25 gene trans-activation is clear, 
a direct effect of FOXP3 needed further investigations. In order to clarify the role of both 
FOXP3 and NF-κB in Cd25 trans-activation, site direct mutagenesis of FOXP3 and κB 
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binding site in Cd25 promoter has been performed.  Moreover, given that FOXP3 has been 
reported to function as a homo-dimer, the impact of an IPEX mutation, that compromises 
FOXP3 homotypic interactions on Cd25 trans-activation, has been also investigated. 
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2.3. Material and methods 
2.3.1. List of reagents 
 Medium DMEM high glucose (Gibco-BRL, Grand Island, NY) 
 PBS (1x): Phosphate buffered saline without Calcium and Magnesium 
 Penicillin/Streptomicin (Sigma Aldrich, St Louis, MO) 
 L-Glutamine (GIBCO)  
 Trypsin 0.05% EDTA (GIBCO) 
 Foetal Calf Serum (FCS) (Euroclone, UK) 
 
2.3.1.2. Antibodies. 
Anti-FOXP3 (H-190), anti-p65/RelA (C20), anti-HA (Y11), and anti-α tubulin 
antibodies were purchased from Santa Cruz Biotecnology (Santa Cruz, CA).  
 
2.3.1.3. Plasmids. 
FOXP3 WT expression plasmid was generously provided by Dr A Rao (La Jolla 
Institute for Allergy and Immunology, La Jolla, CA). FOXP3ΔE251 expression plasmid. was 
kindly provided by Dr SF Ziegler (Benaroya Research Institute, Seattle, WA). HA-tagged 
p65/RelA and p50 expression vectors were kindly provided by Dr G Natoli (Department of 
Experimental Oncology, European Institute of Oncology, Milan, Italy). pGL4-CD25 promoter 
luciferase reporter vector was generated as described below. Plasmid DNA was purified using 
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Plasmid DNA Purification kit (NucleoBond Xtra Midi; Macherey-Nagel). Purified DNA was 
than diluted in dH2O to 0.5-1 μg/μl.      
      
2.3.2. Cloning of the Cd25 promoter, and construction of mutant constructs 
The human Cd25 promoter containing –546 bp from transcription start site (TSS) was 
amplified by PCR using CD25 promoter sequence-specific primers from position –546 to + 
163. The genomic DNA extracted from CD4+ T cells of a healthy donor was used as a 
template. The CD25 promoter amplicon was cloned into the pGL4 basic vector (Promega) to 
generate the pGL4-CD25 promoter luciferase reporter vector. The FOXP3 and κB binding site 
mutants were derived from pGL4-CD25 promoter luciferase construct by substituting five 
nucleotides within the consensus-binding sites by PCR. Primers used to generate the 
individual constructs are listed in Table 1. 
 
Table 1. Primers. Primers CD25 introduced a restriction enzyme recognition site for KpnI or 
XhoI. The primers used for mutational analysis are also shown. In the upper lane, FOXP3 and 
қB binding  sites are evidenced in gray and indicated by position. The primers used for 
mutational analysis are shown in the lower lane and the underlined letters denote mutated 
 70 
nucleotides.FOXP3 23 mutant was obtained by site-directed mutagenesis using FOXP32 and 
FOXP33 primers. 
 
2.3.3. Hek 293 cell line 
The human embryonic kidney cells (Hek 293) were kindly provided by Dr M. 
Crescenzi (Istituto Superiore di Sanità Rome, Italy). The cells were cultured in DMEM 
supplemented with penicillin (100 units/mL), streptomycin (100 μg/mL), L-Glutamine (4mM) 
and 10% FCS. When the cells reached a confluence of 90-100%, the medium was removed 
from the culture and the cells were washed with 10mL of PBS (1x).  To detach the cells from 
the culture dishes (10 cm), 2mL of pre-wormed trypsin 0.05% EDTA was added and left for 2 
minutes until all the cells rounded up. The trypsin activity was neutralized by adding fresh 
DMEM containing 10% FCS. In a new petri-dish, the appropriate volume of fresh medium 
was added to keep the cells at 3 x 105-5 x 105/mL. The petri-dishes were kept at 37 ºC under 
humidified air containing 5% CO2  until the next splitting day which usually was 2 days from 
the first splitting day. 
 
2.3.4. Cell electroporation and luciferase assay 
HEK293 cells were plated at 3 x 105/ mL in petri-dishes (10 cm) to obtain 70% 
confluent layer after 24 hours. 2 x 106 cells were then transfected by electroporation using 5 
μg of total DNA in 450 μl of DMEM supplemented with 20% FCS. For the co-transfection, 
pGL4-CD25 promoter luciferase reporter vector was mixed at ratio 1:2 with FOXP3 WT, 
FOXP3ΔE251, HA-tagged p65/RelA and p50 expression vectors. The pGL4 empty vector 
was added to the preparation to reach the final DNA concentration. Electroporation was 
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performed in 0.45-cm electroporation cuvettes (Gene pulser; BioRad, Hercules, CA) at 960 
μF and 250V. The cells were then incubated at 37 °C and 5 % CO2 and after 24h luciferase 
activity was measured according the manufacturer’s instruction (Promega). Luciferase 
activity, determined in triplicates, was expressed as fold induction over the basal activity of 
cells transfected with empty vectors and/or with pGL4-CD25 promoter luciferase construct 
after normalization to protein concentration. All co-transfections were performed in the 
presence of pEGFP expression plasmid (Clonotech). On overage, about 35% of the cells 
expressed the transfected plasmids, as determined fluorescence-activated cell sorter (FACS) 
analysis of green fluorescent protein (GFP) co- trasfected cells. 
 
2.3.5. Immunoblotting 
The expression of RelA and FOXP3 encoding plasmids was analyzed by 
immunoblotting after 24h from the transfection. An aliquot of each Hek293 cell preparation 
was centrifuged, re-suspended in 30 μl of Lysis buffer (1% NP-40, 20 mM Tris (pH 7.5), 150 
mM NaCl, 5 mM, EDTA, 10 μg ml_1 leupeptin, 10 μg ml_1 aprotinin, 1 mM Na3VO4 and 50 
mM NaF) for 30 minutes in ice. The lysate was centrifuged for 10 min at 14000 x g for 
removal of unlysed cells and the protein concentration of supernatant was determined by a 
BioRad protein assay (BioRad, CA, U.S.A.). Samples were boiled in he presence of SDS 
sample buffer. Proteins (30 μg for each sample) were resolved by 10% SDS-PAGE and 
blotted onto nitrocellulose membranes. Blots were than incubated with anti-FOXP3 anti-HA 
primary antibodies over night at 4º and after incubation with horseradish peroxidase-labeled 
goat anti-rabbit or horseradish peroxidase-labeled goat anti-mouse (Amersham), developed 
with the enhanced chemiluminescence detection system (Amersham). Blots were than 
normalized with anti-tubulin. 
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2.3.6.  Bioinformatics 
Human Cd25 promoter sequence was obtained from GenBank with the accession 
number    NG_007403. The FOXP3 binding sites were identified by using the online pattern 
matching application developed by Dr A Cabibbo, University of Rome Tor Vergata, freely 
accessible at: http://immuno.bio.uniroma2.it/cabibbo/toolies/oligo_finder/. 
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2.4. Results 
 
2.4.1. Characterization of the FOXP3 binding sites on Cd25 promoter 
Accumulating findings suggest that FOXP3 regulates CD25 expression by acting as 
transcriptional activator (Chen et al., 2006; Fontenot et al., 2003). However, no evidence so 
far demonstrated the presence of FOXP3 binding sites on Cd25 promoter. To investigate this 
possibility, we first analyzed the region -340 +80 of human Cd25 promoter containing two 
important positive regulatory regions, PRRI (–276 to –244) and PRRII (–137 to –64), that 
together are required for mitogenic stimulation of CD25 (Kim et al., 2006). As depicted in 
Figure 1A, sequence analysis of Cd25 promoter confirmed the presence of a NF-κB binding 
site at position -267 and showed two tandem copies of the sequence 5’-TGAAAAA-3’ at 
positions -165 and -146. The sequence 5’-TGAAAAA-3’  matched the complement of 
FOXP3 binding sequence 5’-TGTTTCA-3’ in the Il2 promoter except for the substitution at 
position 2 of G with T (Wu et al., 2006) (Figure 1B). Interestingly, the two identified 
sequences were separated at 5’ ends by 19 nucleotides, a distance very close to two helical 
repeats in the B-form DNA. Since it has been demonstrated in vitro that FOXP3 FKH domain 
can simultaneously bind two distinct FOXP3 binding sites separated by a flexible 19-base 
single-stranded DNA linker (Bandukwala et al., 2011; Thomas et al., 2005), we hypothesized 
that the sequence 5’- TGAAAAA -3’ could represent a putative FOXP3 binding site in Cd25 
promoter.  
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Figure 1A. 
 
Fig. 1A. Putative FOXP3 binding sites in Cd25 promoter. The partial human Cd25 
promoter sequence (-340 +80) is shown (GenBank accession nº NG_ 007403). The TSS is 
indicated by broken arrow. The underlined regions represent the κB binding site (-267) and 
the two putative FOXP3 binding sites (-165 and -146). 
 
Figure 1B. 
                               
 
Fig. 1B.  Putative FOXP3 binding sequence in Cd25 promoter matches the complement 
of FOXP3 binding sequence in Il2 promoter except for the presence of G (red circle) 
instead of T. Fragments of Il2 (a) and Cd25 (b) promoters are indicated. Non consensus 
FOXP3 binding sites are underlined. Il2 ARRE2 site is adapted from Wu et al. Cell, 2006. 
 
 
 
a) 
b) 
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2.4.2. RelA and FOXP3 synergize to trans- activate Cd25 promoter 
The NF-kB family contains five members: RelA (p65), RelB, c-Rel, NF-kB1 (p50 and 
its precursor p105), and NF-kB2 (p52 and its precursor p100). These proteins form homo- and 
heterodimers and share a conserved N-terminal Rel-homology domain. NF-κB binding sites 
have been identified in the PRRI region of Cd25 promoter and the classical NF-κB p65-p50 
complexes have been described as the main activators of CD25 transcription (Algarte et al., 
1995). The previous finding that the two putative FOXP3 binding sites mapped downstream 
NF-kB binding site (-267) on Cd25 promoter, suggested the possibility that FOXP3 was able 
to function as co-activator of Cd25 gene in association with NF-κB/RelA. Moreover, a recent 
work from Piccolella laboratory showed that the expression of FOXP3 NF-κB/RelA-mediated 
in CD28-stimulated CD4+CD25- T lymphocytes correlated with CD25 expression on the 
membrane, highlighting a link between FOXP3 and CD25 (Soligo et al., 2011). Starting from 
these evidences, the trans-activatory function of FOXP3 on Cd25 promoter in the presence or 
absence of NF-κB/RelA subunit has been analyzed. To this aim, a new CD25 promoter-
luciferase construct as described in section 2.3.2. of Material and Methods has been prepared. 
Expression vectors encoding NF-κB/RelA, FOXP3 and FOXP3 mutant ΔE251 
(FOXP3ΔE251), an IPEX mutation in the leucin zipper domain that abrogates the FOXP3 
ability to homodimerize (Lopes et al., 2006), have been used to analyse the trans- activation 
of Cd25 promoter.  HEK 293 cells were co-transfected with the CD25 construct and RelA or 
FOXP3 or FOXP3ΔE251, or RelA and FOXP3 or NF-κB/RelA and FOXP3ΔE251 expression 
vectors. After 24h, luciferase reporter gene activity was measured such as NF-κB/RelA and 
FOXP3 protein levels. The result in Figure 2A shows that although the trans-activation of 
Cd25 promoter was dependent on NF-κB/RelA, the presence of FOXP3 expression vector 
alone did not affect Cd25 promoter activity. However, the co-expression of NF-κB/RelA and 
FOXP3 resulted in a synergic effect on Cd25 gene activation. The ability of FOXP3 mutant 
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ΔE251 (FOXP3ΔE251), an IPEX mutation in the leucin zipper domain that abrogates the 
FOXP3 ability to homodimerize (Lopes et al., 2006) to trans -activate Cd25 promoter was 
also tested. As shown in the Figure 2A, the mutant FOXP3ΔE251 encoding vector was not 
transcriptionally functional either alone or in association with NF-κB/RelA (Figure 2A, 
column 4 and 6 respectively). This result suggests that FOXP3 functions as a positive 
activator of Cd25 gene only in conjunction with NF-κB and mutations that disrupt FOXP3 
oligomerization, compromise FOXP3 function. Furthermore,  the effect of the NF- κB p50-
p65 heterodimeric complex, the main form of NF- κB regulating CD25 expression (Algarte et 
al., 1995) on the activation of the CD25 construct in the presence or absence of FOXP3 was 
also tested. To this purpose, the endogenous NF- κB trans-activation over-expressing NF- κB 
/p50 subunit was induced. The result in Figure 2B confirms the ability of NF- κB p50-p65 
heterodimeric complex to trans -activate CD25 construct and shows that the activity of 
FOXP3 on Cd25 promoter is equally dependent on the overexpression of either p50 or p65 
NF- κB subunits (Figure 2B, column 4 and 6 respectively).  
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 Figure 2. 
 
 
Fig. 2. FOXP3 and RelA synergize to trans-activate Cd25 promoter in HEK 293 cells. 
HEK 293 cells were transfected with CD25 promoter luciferase reporter vectors and 
cotransfected with HA-tagged RelA or FOXP3 or FOXP3DE251 (A) or p50 (B) expression 
plasmids, where indicated. Data are the mean (+) SD of luciferase light units normalized for 
Renilla luciferase of the same sample.Results are representative of five independent 
experiments performed in triplicate. An aliquot of each sample (A, lower panel) was analysed 
by immunoblotting with anti-FOXP3, anti-HA and anti α tubulin Abs. 
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2.4.3. Effect of κB and FOXP3 binding site mutagenesis in CD25 promoter 
To better understand the functional role of FOXP3 and NF-κB/RelA on Cd25 gene 
activation, the experiment of Figure 2A upon site direct mutagenesis of FOXP3 and κB 
binding sites in Cd25 promoter was repeated. To this aim, four different constructs as 
described in Table 1 of Materials and Methods, including the sequence 5’-GCAAACT-3’ at 
position -134 that presented a correspondence of the first six nucleotides with a FOXP3 
consensus site, were generated. Hek cells 293 cells were then co-transfected with the mutant 
constructs in the presence of RelA or RelA and FOXP3. In these experiments the levels of 
activation mediated by RelA and FOXP3 were put in relation to those mediated by RelA 
alone in the culture. The result of Figure 3, shows that the mutation of –134 sequence did not 
modify the CD25 reporter gene activation. However, when the two FOXP3 binding sites were 
progressively mutated, a significant decrease of the reporter gene activities was obtained. 
Indeed the mutation of both –165 and –146 sequences brought the level of activation to that 
obtained by RelA alone in culture, suggesting that both binding sites on Cd25 promoter can 
act co-ordinately to exert trans- activation of Cd25 promoter. However, the loss of the 
luciferase activity of CD25 promoter was only obtained by mutation of κB site at position –
267, suggesting that FOXP3-dependent activation of the Cd25 promoter is first dependent on 
the RelA transcription factor complex. Therefore, NF-κB/RelA is the principal activator of 
Cd25 promoter and the binding to its κB site is required to mediate the FOXP3 activatory 
function. Collectively, these data strongly suggest that the positive transcriptional activity of 
FOXP3 on Cd25 promoter could be dependent on the binding of RelA to its κB site and on 
the interaction between FOXP3 and NF-κB/RelA that could favour FOXP3 binding to the two 
tandem copies of the sequence 5’-TGAAAAA-3’ with consequent trans activation of Cd25 
gene. 
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Figure 3. 
 
 
Fig. 3. The binding of FOXP3 to two non-consensus binding sites arrayed in tandem 
concurs to the trans activation of Cd25 promoter. Four different constructs of human Cd25 
promoter region were generated by mutation in a site-directed manner as indicated. Both wildt 
ype and mutated luciferase reporter vectors were transfected into HEK 293 cells. Where 
indicated, the cells were cotransfected with HA-tagged RelA and FOXP3 expression 
plasmids. Data are the mean 6 SD of luciferase light units normalized for Renilla luciferase of 
the same sample. Effect of mutagenesis is shown as percentage relative to wild-type 
construct, cotransfected with HA-tagged RelA and FOXP3, and arbitrarily set to 100%. 
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2.5. Discussion 
Investigation of the role of activation-induced FOXP3 has been overshadowed by the 
prominent role of FOXP3 in Treg cell function and by the fact that this phenomenon was 
thought to occur in humans but not mice. FOXP3 regulates expression of several cell-surface 
markers characteristic of Treg cells by acting as either a transcriptional repressor or activator. 
Nevertheless, the mechanisms by which FOXP3 acts need further investigations. Thus, the 
research presented in the first part of this thesis aimed to investigate how FOXP3 activates 
target gene expression, analyzing in particular the mechanisms that could account for a direct 
regulation of CD25 expression. Considerable evidence supports the prediction that CD25 is 
directly regulated by FOXP3. Ectopic expression of FOXP3 in CD4+CD25- naïve T cells has 
been shown to convert these cells to CD4+CD25+ T cells (Fontenot et al., 2003; Hori et al., 
2003). Moreover FOXP3 can be recruited on specific binding site on Cd25 promoter after T 
cell activation and mediate histone acetylation of the involved region (Chen et al., 2006; Wu 
et al., 2006). Given that CD25 is normally up-regulated in all activated T cells, regardless of 
whether they express FOXP3, and the difficulty of analysing in vitro signal transduction 
pathways that specifically target FOXP3 to Cd25 promoter, this issue has still to be 
definitively demonstrated. Previous studies have shown that a promoter/enhancer region of 
Cd25 gene, spanning the nucleotides –276 –64 relative to the major transcription initiation 
site, controlled at least in part CD25 expression in T cells (Lin et al., 1990). This critical 
region contains an NF-κB binding site at position –267 –257 (Algarte et al.,1995) and the 
occupancy of this site by various Rel/NF-κB is required to trans activate Cd25 in conventional 
CD4+ T cells. Sequence analysis of Cd25 promoter allowed the identification of two non-
consensus FKH sites (5’- TGAAAAA -3’) at positions –165 and –146 down-stream of the 
known κB-binding site at position –267. Moreover, by using a reporter construct composed of 
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the promoter/enhancer region of Cd25 gene, the results of this thesis have not only confirmed 
the role of NF-κB factors as potent activators of Cd25 promoter in conventional CD4+ T cells, 
but have also showed FOXP3 as a direct activator of Cd25 gene. However, the capacity of 
both RelA and FOXP3 to regulate Cd25 gene raises a question: how to reconcile the role of 
RelA and FOXP3 in the regulation of CD25 expression in Treg. The reported data 
demonstrating that the simple bind of FOXP3 to Cd25 promoter is not sufficient to activate 
CD25 expression, support the hypothesis that FOXP3 could acquire activatory function in a 
cooperative complex with RelA, and both RelA and FOXP3 function as direct activator of 
Cd25 promoter in Treg. Therefore the complex FOXP3-RelA-DNA could represent a minimal 
complex required to stimulate Cd25 gene in Treg as the complex FOXP3-NFAT-DNA has 
been described as a minimal complex required to inhibit Il2 gene in the same cells (Chen et 
al., 2006; Wu et al.,2006) although with different requirements for the interaction FOXP3-
RelA-DNA and FOXP3-NFAT-DNA. Indeed, FOXP3 and RelA interact on sites that are 
separated in Cd25 promoter, while FOXP3 and RelA interact on ‘composite’ DNA elements 
with adjacent binding sites for FOXP3 and NFAT in Il2 promoter (Wu et al., 2006). However, 
the presence of NFAT binding site located at approximately –650 and –585 upstream of the 
promoter region in the mouse Cd25 gene, suggests that additional transcription factors could 
be linked to FOXP3 and assemble complex larger than FOXP3-RelA-DNA to up-regulate 
CD25 expression. It has been proposed that the degenerate nature of FOXP3 binding sites in 
vivo  (Marson et al., 2007; Zheng and Rudensky, 2007) may reflect the contributions of 
additional co-factors at specific loci (Koh et al., 2009). Therefore large-scale ‘ChIP-chip’ 
assay have been used to identify DNA elements likely to bind FOXP3 in vivo, either alone or 
in complex with transcriptional partners (Marson et al., 2007; Zheng and Rudensky, 2007). 
FOXP3 binding in vitro has been observed only on consensus sites, and EMSA experiments 
confirm that both the DNA-binding FKH domain and intact leucin-zipper domain, which 
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mediates homo-multimerization of FOXP3 are required for DNA binding (Koh et al., 2009) 
supporting the view that FOXP3 can bind DNA with high affinity as at least a dimer 
(Bandukwala et al., 2011; Li et al., 2007). With respect to this, the two non-consensus FKH 
sites (5’- TGAAAAA -3’) identified were separated at 5’ ends by 19 nucleotides. This FOXP3 
binding region, where two FOXP3 molecules, bound to the two distinct binding sites, could 
dimerize, presents the requirements necessary to allow the binding and stabilization of 
FOXP3 to its binding Indeed, although the identified FOXP3 target sequences are not 
consistent with a FKH consensus motif (Koh et al., 2009; Sadlon et al., 2010), these sites 
could become permissive in vitro to FOXP3 bind at least in two distinct modes: through post-
translational modifications of FOXP3 and through the distinctive preference of FOXP3 for 
tandem sequences in DNA. The reported data highlight also the importance of dimer 
formation for transcriptional regulation by FOXP3 of target genes. Indeed it has been found 
that FOXP3 ΔE251, a FOXP3 mutant that compromise homotypic interactions (Lopes et al., 
2006) poorly associated with the Il2 promoter in human T cells and was less efficient at 
repressing IL-2 transcription (Li et al., 2007). In this thesis it has been demonstrated that 
FOXP3ΔE251 fails to upregulate CD25 expression induced by RelA. Therefore, this evidence 
suggests that the homodimerization of FOXP3 is crucial for the binding of FOXP3 to DNA 
but is not implicated in mediating inhibitory or activatory functions. In conclusion, the 
reported results have provided novel information on the mechanisms by which RelA and 
FOXP3 cooperate to mediate transcriptional regulation of target genes. Moreover it has been 
identified a region on Cd25 promoter where FOXP3 dimer could bridge intra-molecularly two 
DNA sites and trans activate Cd25 promoter. Together these studies contribute to the larger 
body of literature that demonstrates the crucial role of FOXP3 in immune cell function. A 
better understanding of how FOXP3 mediates its functions at both cellular and molecular 
level will be of utmost importance to harnessing the power of Treg cells for therapies and 
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manipulating both Treg and Tconv cells in diseases settings.  
3. Part II:  Development of methods to expand stable and 
suppressive human CD4+CD25+FOXP3+ Treg cells 
 
3.1 Introduction 
Given the concerns regarding the stability and function of ex vivo expanded Treg cells, 
several purification and expansion protocols have been tested during the past years. For 
example, the application of tolerance permissive drugs has been shown not only to enhance 
Treg expansion and function in vitro but also to increase the purity of these cells by 
eliminating non-Treg cells present in the starting population. However, while is possible to 
examine the effect of specific agents on Treg cells in vitro, extrapolation of results to the in 
vivo setting is problematic because of the difficulty in identifying true dose comparisons. So, 
careful consideration will need to be given to the immunosuppressive drug regimen.  
         
3.1.1. Rapamycin (RAPA) 
Rapamycin (RAPA) is an mTOR (mammalian target of rapamycin) kinase inhibitor 
which is downstream of phosphatidylinositol 3-kinase (PI3-K), a signaling molecule activated 
by CD28 or IL-2 receptor engagement in T cells (Thomson et al., 2009). IL-2 receptor 
engagement activates both PI3-K and Janus kinase-STAT pathways. Whereas PI3K-mTOR 
pathway is attenuated in Treg cells, Janus kinase-STAT pathway remains intact, suggesting 
that these cells preferentially signal through the latter and may be resistant to mTOR 
inhibition (Zeiser et al., 2008). This notion is supported by genetic ablation and cellular 
experiments that demonstrate mTOR deficiency or addition of rapamycin favors the 
 84 
outgrowth and function of Treg cells (Battaglia et al., 2005; Delgoffe et al., 2009). Consistent 
with these in vitro observations the use of rapamycin in mouse transplant models was found to 
promote expansion of suppressive Treg cells (Coenen et al., 2007; Gao et al., 2007; Kopf et 
al., 2007). Interestingly, Valmori et al. demonstrated that rapamycin can also induce 
suppressive functions in conventional human CD4+ T cells (Valmori et al., 2006). Therefore, it 
cannot be excluded that this drug can both expand Treg cells and induce them from human 
CD4+ T cells. It has recently shown that rapamycin is able not only to increase the number of 
Treg cells, but also to enhance their donor-specific suppressive capability in vivo (Monti et 
al., 2008). So, there is substantial evidence that rapamycin favors Treg expansion and 
function and, by suppressing effector T cells, tips the balance from an aggressive towards a 
more protective type of allo-response. 
 
3.1.2. All trans retinoic acid (ATRA ) 
Retinoic acid, a derivative of vitamin A, promotes differentiation of naïve human and 
murine T cells into Treg cells (Mucida et al., 2007; Mucida et al., 2009) and, more recently, 
has been shown to increase in vitro Treg function (Wang et al., 2009). Two non-mutually 
exclusive mechanisms have been proposed to account for the ATRA-promoted induction of 
suppressive T cells. Some data indicate that ATRA augments TGF-β signaling (Benson et al., 
2007; Xiao et al., 2008), while other studies report that ATRA suppress the ability of memory 
T cells to block the induction of FOXP3-expressing Treg cells (Hill et al., 2008). Suppressive 
T cells generated in vitro by ATRA are attractive immunotherapeutic agents because of their 
ease generation and their potent function in murine models of autoimmunity, but concerns 
remain regarding their stability. It has been shown that ATRA is capable to skew the Treg-
Th17 axis of naïve T cell differentiation toward the former (Mucida et al., 2007). Addition of 
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ATRA inhibits development of Th17 cells from naïve precursors in a skewing environment 
TGF-β and IL-6. The mechanism of this effect is not completely understood but it is 
established to be independent of STAT signaling (Elias et al., 2008). ATRA may inhibit IL-6 
receptor α chain expression, enhance Smad3 activity in response to TGF-β and/or directly 
interact with the Foxp3 promoter (Xiao et al., 2008). In regards to this, selective retinoic acid 
receptor α (RAR α) gene deletion in animals’ models has been showed to decrease Foxp3 
expression in Treg cells (Hill et al., 2008). This evidence suggests that ATRA may favor 
FOXP3 stability and ex vivo expansion of highly suppressive Treg cells. However, as ATRA 
plays an important role in T helper cell fate decisions inducing both effector T cell activation 
and differentiation to Th1 and Th17, its use for Treg expansion warrants further investigation.  
 
3.2. Research goal 
The use of expanded CD4+CD25+FOXP3+ regulatory T cells as a cellular therapy is an 
attractive approach for autoimmunity disease and for limiting immune responses to allograft 
after transplantation. The major challenge of clinical trials is deciding the basis on which Treg 
cells should be isolated to maintain pure populations after in vitro expansion. Purity is an 
issue because of potential out-growth of non-Treg cells that could contribute to rejection or 
cause autoimmunity. Thus, the goal of this research was to investigate the effect of tolerance 
permissive drugs, Rapamicyn (RAPA) and all-trans retinoic acid (ATRA), on the expansion of 
human CD4+CD25+FOXP+ regulatory T cells in vitro. I wanted to examine whether the 
treatment with these drugs modified the expression of distinct molecular markers on expanded 
Treg cells, including chemokine receptors, and whether they affected the purity and the 
suppressive function of ex vivo expanded Treg cells. Even if extremely pure populations can 
be obtained, there is a great debate over the stability of Treg cells. Indeed, one factor to 
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consider is that different subpopulations of CD4+CD25+FOXP3+ regulatory T cells may be 
more stable than others. In order to clarify the different effect of drug treatment on Treg 
plasticity,  the behavior in vitro of three phenotypically and functionally Treg subsets 
described by Miyara et al was studied. In particular it has been investigated whether RAPA 
and/or ATRA treatment differently selected the expansion of  a particular Treg subset. It has 
been also investigated  whether drug treatment affected the function of these Treg 
subpopulations by analysing the potential of these cells to release pro-inflammatory cytokine. 
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3.3. Material and methods 
3.3.1. List of reagents 
3.3.1.1. Medium and solutions 
 Medium X-Vivo 15 (Lonza, Switzerland)  
 Dulbecco’s PBS (1x): Phosphate buffered saline without Calcium and Magnesium 
(PAA, Austria) 
 Staining buffer: PBS (1x) with 0.5% fetal calf serum (FCS) (SeraQ, Sussex, UK) and 
0.4% EDTA (ethylenediamine tetra-acetic acid) 0.5M (Gibco) 
 Freezing solution: 10% DMSO and 90% FCS 
 
3.3.1.2.  Other reagents 
 Lymphocyte (PAA, Austria). 
 miniMACS CD4+CD25+ T Regulatory Cell Isolation Kit (Miltenyi-Biotec, UK) 
 Duo-Set ELISA kits from R&D (R&D system) 
 Dynabeads Human T activator anti CD3/CD28 beads (Invitrogen) 
 Mouse pan-IgG magnetic beads (Dynal Biotech, Norway) 
 Carboxyfluorescein diacetate, sucinnimydil ester (CFSE) (Molecular Probes, USA) 
 Dimethyl sulfoxide (DMSO) (Sigma) 
 Foetal Calf Serum (FCS) (SeraQ, UK) 
 Penicillin and Streptomicin (Sigma Aldrich, St Louis, MO) 
 Human AB serum (HS) (Biosera, UK) 
 Bovine serum albumin (BSA) (Sigma) 
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 Phorbol Myristate acetate (PMA, Sigma) 
 Ionomycin (Sigma) 
 Monensin (eBioscience). 
 Rapamycin (RAPA) LC-Laboratories, USA) 
 All-trans retinoic acid (ATRA) (Sigma-Aldrich, USA) 
 IL-2 (Proleukin-Novartis, UK) 
 
3.3.2. Flow Cytometry 
3.3.2.1. Reagents 
 The following mouse monoclonal antibodies, direct against human antigens 
conjugated to fluorescein isothiocyanate (FITC), phycoerytrin (PE), allophycocyanin (APC), 
a tandem fluorochrome that combines PE and a cyanine dye (PE-Cy7 or PE-Cy5) and 
peridinin-chlorophyll-protein complex (PerCP) were used: CD3-FITC, CD4-FITC (both 
Sigma-Aldrich); CD25-PE (4E3; Miltenyi-Biotec,UK); CD62L-FITC (Greg-56; 
Invitrogen,UK); CD152-PE (14D3), CD127-PE-Cy7 (eBioRDR5), GITR-APC (eBioAITR), 
ICOS-PE-Cy7 (ISA-3), CD39-FITC (eBioA1), Integrin α4/CD49d-PE (9F10), CD161-APC 
(HP-3G10), IFN-γ-FITC (4S.B3), IL-17-PE (eBio64DEC17) and FOXP3-FITC (PCH101 and 
236A/E7) (all eBioscience, USA); CD27-PE (M-T271) and Integrin β7-PE-Cy5 (FIB504) 
(both BD-Bioscience, UK); CLA-FITC (HECA-452) and CCR4-PerCP-Cy5.5 (TG6/CCR4) 
(all Biolegend, USA) and appropriate isotype controls from mouse or rat were used. Prior to 
use, all mAbs were titrated using normal resting or activated PBMC to establish optimal 
staining dilutions. Flow cytometric data were acquired on a FACScalibur flow cytometer 
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running CellQuest software (Becton Dickinson) and analyzed subsequently with FlowJo 
software (Treestar Inc, Ashland, OR). 
 
3.3.2.2. Intracellular cytokine staining (ICS) 
 For ICS, cells were stimulated with PMA and Ionomycin for 5 hours at 37 ºC in the 
presence of Monensin at final concentration of 50ng/mL, 1 μM and 2μM respectively. Cells 
were then washed twice with PBS, once with 1% FCS/PBS and blocked on ice for 15 minutes 
with 50% FCS in PBS. Permeabilization was carried out by resuspension in PBS 1% 
FCS/0.1% saponin (Sigma). Monoclonal antibodies against human cytokines IFN-γ and IL-17 
and isotype controls were then added in a staining volume of 30 μl and incubated for 30 
minutes at 4 ºC in the dark. Cells were then washed once with PBS 1% FCS/0.1% saponin 
and resuspended in PBS. Flow cytometry was carried out within 2 hours of staining. 
 
3.3.2.3. Surface and FOXP3 Intracellular staining 
 After harvest, cells were washed and surface stained with the above listed mAbs for 15 
minutes at 4°C in the dark. Appropriate isotype control antibodies were used for each sample. 
Following staining, cells were examined by flow cytometry. 
 FOXP3 staining was performed using the eBioscience human FOXP3 staining kit. 
Briefly, cells were surface stained if required, washed once in PBS and then vortexed and 
incubated in 1mL of Fixation/Permeabilization solution for 30 minutes at 4 ºC in the dark. 
Cells were then washed twice with Permeabilization buffer 1x and incubated with anti-human 
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FOXP3 antibody for 30 minutes at 4 ºC in the dark. The cells were washed once with 
Permeabilization buffer 1x and resuspended in the same solution for FACS analysis.  
 
3.3.3. Enzyme-linked ImmunoSorbent Assay (ELISA) 
IL-17 and IFN-γ in supernatants were analyzed by an indirect sandwich ELISA, using 
purified and biotinylated anti-IL-17 and anti-IFN-γ (BD Pharmingen, USA). ELISA for 
human IFN-γ and IL-17 was carried out using the kit from R&D system. Nunc Maxisorb TM 
plates were coated overnight at room temperature (RT) with 100 μl/well anti-IFN-γ and anti-
IL-17 antibodies at final concentrations at 4μg/mL in PBS. Plates were then washed three 
times with 0.5% Tween Sigma (Sigma) in PBS and blocked for one hour at rtp with 
300μl/well freshly made 1% BSA in PBS. Plates were washed three times as before and 
blotted to dry before addition of 100μl/well of samples and standards in duplicate. Standards 
curves were prepared by serial two-fold dilutions of the manufacturer’s standards in 1% BSA 
in PBS from a top concentration of 1000 pg/mL to15.63 pg/mL and one concentration of 
0pg/mL (diluent alone). Plates were incubated for two hours at RT and then washed three 
times as before. 100μl/well detection antibodies biotinylated anti-IL-17 and anti-IFN-γ were 
added at final concentrations of 75ng/mL and 175ng/mL respectively in PBS/1% BSA and 
incubated for two hours at rtp. Plates were then washed three times with 0.5% Tween/PBS 
and 100μl manufacturer’s streptavidin-HRP (horseradish peroxidase) diliuted 1 in 20 (in 
1%BSA/PBS) was added to each well and incubated at rtp for 20 minutes. Plates were again 
washed three times and blotted to dryness before addition of 100μl substrate solution (TMB) 
(Zymed, USA) to each well. A further incubation for 20 minutes at RT in the dark was 
followed by addiction of 50μl 0.5M sulphuric acid (H2SO4) to each well to terminate the 
reaction. Optical density at 450nm was measured on a Bio-Tek EL800 automatic plate reader 
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(Wolf Laboratories, UK). The concentration of each cytokine was calculated from standard 
curves constructed from the optical densities of the known concentrations.  
 
3.3.4. Cell culture 
3.3.4.1. PBMCs separation  
 Human buffy coats, coming from healthy donors, were provided by the National 
Blood Transfusion Centre (South Thames, Tooting, UK). Diluted blood 1 in 7 with PBS was 
layered onto 15mL of Lymphocyte followed by centrifugation at 2000 rpm at 20ºC for 20 
minutes with slow acceleration and no brake. Peripheral blood mononuclear cells (PBMC) 
were derived by harvesting of interface cells followed by washing with PBS three times at 
2000 and 1800 rpm twice respectively for 10 minutes at 4 ºC at normal acceleration and 
deceleration.  
 
3.3.4.2.  Isolation of CD4+CD25+T cells 
 Different techniques have been used for the isolation of human regulatory T cells. 
 
3.3.4.2.1. Isolation using Magnetic activated cell sorting  
 CD4+CD25+ regulatory T cells were isolated using miniMACS CD4+CD25+ T 
Regulatory Cell Isolation Kit. The kit contains a cocktail of biotinylated antibodies and anti-
biotin micro-beads for depletion of non-CD4+ T cells, and CD25 micro-beads for subsequent 
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positive selection of the CD4+CD25+ regulatory T cells. PBMC were incubated with 90μl 
Staining buffer and 10μl of biotin antibody-cocktail /107 cells for 10 minutes followed by 15 
minutes incubation with anti-biotin micro-beads at 4 ºC. The biotin antibody-cocktail 
contained biotin-conjugated monoclonal anti-human antibodies against CD8, CD14, CD16, 
CD19, CD36, CD56, CD123, TCR γ/δ and CD235a (glicophorin A). The cells were then 
washed once with Staining buffer (centrifugation 1800 rpm for 5 minutes at 4 ºC) and 
resuspended in 500μl Staining buffer/108 cells. An LD MACS separation column was 
prepared by single rinse with 2mL Staining buffer and placed on a MACS separator magnet. 
The resuspended cells were passed over the column and the negative fraction (unbound CD4+ 
cells) eluted with a series of two x 1mL Staining buffer washes.  
 The eluted cells were then centrifuged and resuspended in 90 μl Staining buffer and 10 
μl of CD25+ micro-beads/107 cells and incubated in dark for 15 minutes at 4 ºC. The cells 
were then washed once with Staining buffer (centrifugation 1800 rpm for 5 minutes at 4 ºC) 
and resuspended in 500 μl Staining buffer /108 cells. The cells were then passed through an 
MS column (prepared by single rinse with 500 μl Staining S buffer) and the negative selection 
(CD4+CD25- responder T cells/Tres) eluted with a series of three x 500 μl Staining buffer 
washes. Aliquots of these cells were cryopreserved and used as autologous responder cells in 
suppression assays (sections 3.3.5 and 3.3.6). The column was the removed from the magnet 
and the CD25-microbeads positive fraction, CD4+CD25+ regulatory T cells, eluted with 1mL 
of Staining buffer and firm column pressure from the plunger. CD4+CD25+ T cells were 
analyzed by flow cytometry following staining with anti-human CD4 and anti-humanCD25 
antibodies. Their purity was between 90-98%.  
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3.3.4.2.2. Separation of CD4+ T cells using  Dynabeads 
3.3.4.2.2.1. Antibodies 
The following mouse anti-human CD marker monoclonal antibodies were purchased 
for cell purification and enrichment procedures: CD8 (3B5), CD14 (B-A8), CD16 (B-E16), 
CD19 (B-C3), CD56 (B-A19), CD33 (4D3) (Invitrogen, USA), CD235a (GA-R2), TCR γ/δ 
(IIF2, Becton-Dikinson (BD), CA).  
 
3.3.4.2.2.2. Enrichment of CD4+ T cells 
 CD4+ T cells were enriched from human PBMC by negative selection using an 
antibody cocktail. Cells were incubated in 5mL MACS buffer containing antibodies against 
CD8 (6 μl/108 cells), CD14 (7 μl/10^8 cells), CD16 (7 μl/108 cells), CD19 (18 μl/108 cells), 
CD33 (3 μl/108 cells), CD56 (3 μl/10^8 cells), TCR γ/δ (7 μl/108 cells), CD235a (7 μl/108 
cells) for 30 minutes at 4 ºC on a roller. Cells were then washed with MACS buffer 
(centrifugation 1800 rpm for 5 minutes at 4 ºC) and resuspended in 5mL X-Vivo 15 medium 
supplemented with 5% HS containing mouse pan-IgG magnetic beads. Beads were used at 
1μl/106 cells and washed twice with 5mL PBS in a magnet before addition to cells. A passage 
through a magnet to remove unwanted cells was fallowed by incubation for 30 minutes at 4 
ºC on a roller. Isolated CD4+ T cells were incubated over night at a final concentration of 5 x 
106 cells/mL in X-Vivo 15 medium supplemented with 5% (HS) at 37 ºC in 5% CO2. 
 
 
 94 
3.3.4.3. Cell sorting of human Treg subpopulations 
 Fluorescence activated cell sorting of subpopulations of CD4+ T cells were carried out 
using a 3-laser FACS-Aria high-speed cell sorter (BD Biosciences). For each cell sort, single 
positive and unstained controls were used to set up the gates and instrument compensations. 
Cell staining of 200 x 106 cells was carried out in 10mL MACS buffer for 20 minutes at 4 ºC 
on a roller, followed by a single wash, resuspension in 10mL MACS and cell sorting. CD4+ T 
cells, enriched from human buffy coats as previously described (section 2.2.2.), were stained 
with monoclonal antibodies conjugated to fluorescence dyes directed against specific cell 
surface markers. To sort Treg subpopulations, CD4+ T cells were stained with anti-CD4 
(FITC), anti-CD25 (APC) and CD45RA (PE) antibodies to sort them into 
CD4+CD25+CD45RA+, CD4+CD25+CD45RA- and CD4+CD25hiCD45RA- T cells.  
 
3.3.5. Cryopreservation of cells  
 PBMCs and CD4+CD25- responder T cells were centrifuged at 1800 rpm for 5 
minutes. The pellet was resuspended in freezing solution at final concentrations of 50x10^6 
and 10x10^6/mL respectively. Cells were transferred to a -80 ºC freezer for a minimum of 
24hours. The cryovials were then stored into liquid nitrogen tanks.  
 
3.3.6. Suppression assay 
 For functional assay, cryopreserved responder T cells (Tres cells) were thawed and 
labeled with CFSE as follows. Cells were washed twice in PBS, before being stained with 2.5 
μM CFSE in PBS at 10x107/mL. After 3 minutes at room temperature in the dark, the reaction 
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was stopped by washing three times the cells with X-Vivo 15 supplemented with 5% HS. The 
cells were then resuspended in the same medium at the required concentration. In order to 
quantify differences in susceptibility to suppression, Tres cells, labeled with CFSE, were 
cultured alone or in co-cultured at different ratios with Treg cells treated with or without 
RAPA (100nM) and/or ATRA (2μM). In each case, the number of Tresp cells was kept 
constant (1x105) and the number of Treg cells titrated down (Treg:Tres ratio= 1:1, 1:3 and 
1:10) in X-Vivo15 supplemented with 5% HS. The cells were stimulated with anti-
CD3/CD28 beads in U-bottom 96-well plates and incubated at 37°C, 5% CO2 for 5 days. 
After harvest, qualitative CFSE dilution was assessed by flow cytometry on day 5 through 
acquisition of fluorescence in FL1 channel. For qualitative estimation of proliferating 
precursors, 20μl of counting beads (Cytognos, Spainn) was added to each FACS tube. The 
number of acquired cells in each CFSE peak was multiplied by the ratio of acquired to added 
counting beads prior analysis. For concurrent estimation of apoptosis, cells were also stained 
with 7-Amino-actinomycin D (7-AAD) (Beckton Dickinson) for 3 minutes at room 
temperature prior to flow cytometry. The percentage of suppression was calculated based on 
the proliferation of responder T cells alone compared with the proliferation of cultures 
containing responder and suppressor cells. 
 
3.3.7. Expansion of Treg cell lines 
 Healthy human CD4+CD25+ T cells, purified as described in section 3.3.4.2., were 
plated at 1x106/ml in X-Vivo 15 supplemented with 5% HS with or without RAPA (100nM) 
and/or ATRA (2μM). RAPA (100nM) final concentration was used according to previous 
reports (Battaglia). Different doses of ATRA (0.002-2μM) were investigated and 2μM chosen 
for in vitro Treg expansion because of its strong biological effect on Treg phenotype. Cells 
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were initially stimulated with anti-CD3/CD28 beads at a bead: cell ratio of 1:1. IL-2 
(1000IU/mL) was added at day 2 post-activation and replenished every 2 days.  Beads were 
removed by magnetic adherence every 7 days post-activation and fresh anti-CD3/CD28 beads 
(1:1 ratio), RAPA, ATRA and IL-2 (1000 IU/ml) were added. Cells were cultured for 
between 3 or 5 weeks prior to use. 
 
3.3.8. In vitro Treg stability assay  
 Fresh (5x105), untreated, RAPA and/or ATRA treated Tregs were activated with anti-
CD3/CD28 beads at a bead:cell ratio of 1:1 and cultured for 5 days in X-Vivo 15 medium 
supplemented with 5% human serum with the following cytokine cocktails: Cocktail-A IL-2 
(10 IU/ml), IL-1β (10ng/ml), IL-6 (4ng/ml) and TGF-β (5ng/ml, all R&D-Systems, USA); 
Cocktail-B IL-2 (10 IU/ml), IL-21 (25ng/ml, Cell-Sciences, USA), IL-23 (25ng/ml, R&D) 
and TGF- β (5ng/ml, R&D). Cells cultured in complete medium supplemented with IL-2 (10 
IU/ml) were used as control. 
 
3.3.9. Statistical analysis 
 Statistical analysis was carried out using GraphPad Prism software (GraphPad 
software Inc., USA). Parametric and non-parametric data were calculated as the mean±s.d. 
and median (interquartile range, IQR) respectively. For comparison of parametric and non-
parametric data, t-test, one- or two-way ANOVA with Bonferroni test comparison and 
Kruskal-Wallis test were used where appropriate. 
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3.4.  Results 
3.4.1. RAPA and/or ATRA treatment do not modify FOXP3 expression in human Treg 
cells 
It has been observed that Treg cells isolated by magnetic bead based-enrichment of 
CD4+CD25hi lose FOXP3 expression when expanded ex vivo (Hoffmann et al., 2009) 
Although FOXP3 in the human system is not exclusively expressed by Treg cells, but it can 
be also up-regulated by activated non Treg cells, the evaluation of the percentage of FOXP3+ 
cells is still the best way of controlling the purity of these cells (Morgan et al., 2005; Ziegler, 
2006). In order to work towards an optimal protocol for the expansion of bead-separated Treg 
cells, we tested the effects of two drugs on ex vivo purified human Treg cells. RAPA and more 
recently ATRA have been shown to enhance human CD4+CD25hiFOXP3+ T cells expansion in 
vitro (Battaglia et al., 2005; Golovina et al., 2011). Thus, the effects of RAPA and ATRA on 
human Treg cell phenotype with regard to FOXP3 and CD25 expression were first analyzed 
and compared. Polyclonal Treg cell lines, with a purity of more than 90% for FOXP3-
positivity on isolation, were generated as described in Material and Methods. These cells were 
activated using anti-CD3/CD28 beads and IL-2 (1000 IU/mL), in the absence (untreated) or 
presence of RAPA (100nM), ATRA (2μM) or a combination of both drugs (RAPA+ATRA). 
Phenotypic analysis of fresh isolated Treg cells or Treg cell lines cultured for 28 days under 
different conditions (Figure 1A) showed no significant differences in the percentage of CD25 
and FOXP3 expression. However, the mean fluorescent intensity (MFI) of CD25 expression 
was highest following exposure of Treg cell lines to RAPA alone or in combination with 
ATRA (Figure 1B). In contrast, FOXP3 MFI was mostly unchanged by the addition of RAPA 
alone or RAPA plus ATRA. As the different Treg cell lines maintained high levels of FOXP3 
expression, it follows that the treatment of these cells with RAPA, ATRA or the combination 
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of both drugs could help to maintain Treg phenotype during ex vivo expansion. 
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Figure 1.                                   
       
 
Fig. 1. CD25 and FOXP3 expression of untreated, RAPA-, ATRA- and RAPA+ATRA-
treated human Treg cells. (A) Expression of indicate molecules was determined in both 
fresh cells, untreated or drug-treated Treg cell lines. The cells were stimulated with anti-
CD3/CD28 beads and IL-2 (1000 IU/mL) for 28 days in the presence or absence of drugs 
(RAPA 100nM and/or ATRA, 2μM) and analyzed by flow cytometry. Representative FACS 
dot plots from 7 independent experiments of FOXP3 and CD25 co-expression are shown. (B) 
CD25 and FOXP3 expression calculated as mean fluorescent intensity in Treg cell 
preparations. Asteriks indicate a significant difference compared to untreated cells (UNT) and 
A 
B 
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between different Treg drug treatment *p<0.05, **p<0.01.  
 
 
3.4.2. Human Treg cells are expanded in the presence of RAPA and/or ATRA. 
As human Treg cells represent only 5-10 % of the circulating CD4+ T cells, their 
potential use as a therapy is limited. In order to reach therapeutic cell numbers, isolated Treg 
cells need to be expanded. Thus the effects and mechanisms of action of RAPA, ATRA and 
the combination of both drugs on the expansion rate of human bead-enriched Tregs, were 
analyzed and compared. These cells were cultured with anti-CD3/CD28 and IL-2 (1000 
IU/mL), in the absence (untreated) or presence of RAPA (100nM), ATRA (2μM) or both 
(RAPA+ATRA). Treg cells were harvested weekly for up to 28 days and the total cell number 
measured. Analysis of the population doublings (Figure 2A), demonstrated that cell 
expansion reached a peak between the second and third re-stimulation. The same analysis 
showed that the mean expansion after 28 days of culture for 10 Treg lines was comparable 
between different culture conditions although some variability was observed between Treg 
preparations derived from different donors (Figure 2B) This result suggests that RAPA, 
ATRA and the combination of both drugs can promote ex vivo human Treg proliferation. 
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Figure 2.                                   
 
 
 
 
 
Fig. 2. Expansion of RAPA-, ATRA- and RAPA+ATRA-treated Treg cells in vitro. (A) 
Treg cell lines were stimulated with anti-CD3/CD28 beads and IL-2 (1000 IU/mL) in the 
presence or absence of drugs Rapa (100nM) and/or ATRA (2μM) and cultured for 28 days. 
Cell counts were performed at weekly intervals (R) throughout culture period. The in vitro 
expansion of 10 different Treg cell lines was calculated as populations doubling. (B) 
Expansion rates of 10 different Treg cell lines cultured as described above. Mid lines indicate 
median expansion. 
 
 
A B 
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3.4.3. ATRA and RAPA treatments affect Treg suppression function in vitro 
To compare the regulatory function of each Treg cell line preparation, responder 
CD4+CD25- T cells were stained with CFSE as described in Material and Methods and 
stimulated with anti-CD3/CD28 beads in the presence or absence of expanded Treg lines 
(after 4 re-stimulations, d28) at varying ratios. After 5 days of co-culture, the ability of the 
different Treg cell lines to suppress a polyclonal stimulus was determined by CFSE dilution 
by flow cytometry. As depicted in Figure 3A, RAPA- and RAPA+ATRA-treated Treg cells 
had the greatest suppressive activity on Teff proliferation, followed by ATRA-conditioned 
Tregs. In comparison, Treg cells expanded in the absence of ATRA and RAPA had a 
significantly reduced suppressive ability. This evidence suggests that Treg treatment with 
RAPA, ATRA or the combination of both drugs affects positively their function in vitro. 
However, following adoptive transfer of ex vivo expanded Treg cells, it is possible that these 
cells may revert to an ‘untreated’ Treg phenotype in the prolonged absence of the conditioning 
drug used for expansion. To verify that our expanded Treg cells do not lose their ability to 
function in vitro, Treg suppressive function was re-evaluated following two additional weeks 
of culture in the absence of drugs. As shown in Figure 3B each Treg line tested uniformly 
maintained high suppressive activity following drug withdrawal from cell cultures. These data 
indicate that our Treg cell lines preparations “starved” of RAPA, ATRA, and RAPA plus 
ATRA are stable in their function suppressing effector T cell proliferation in vitro. 
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Figure 3. 
                                    
 
Fig. 3. Effect of RAPA, ATRA and RAPA+ATRA on Treg cell line suppressive ability in 
vitro. (A) Suppression of Teff cell proliferation by Treg cell lines cultured for 28 days in the 
presence or absence of drugs was determined by CFSE dilution. Treg cells were co-cultured 
with CFSE labeled Teff cells at the indicate ratios of Teff : Treg cells and stimulated with anti-
CD3/anti-CD28 beads. Five days later, CFSE dilution was determined by flow cytometry. (B) 
Suppression of Teff cell proliferation by 28-day Treg cell lines that were either kept in the 
presence of drugs (w/) or “starved” of RAPA, ATRA and RAPA+ATRA (w/o) for a further 2 
weeks. Bar graphs show mean ± s.d. of 9 independent experiments. Data are expressed as 
average percent of suppression of proliferation of Teff cells alone. Asterisks indicate 
significant differences in suppressive ability of Treg preparations compared to untreated cells 
and between different Treg drug treatments *p<0.05, **p<0.01, ***p<0.001 
A 
B 
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3.4.4. RAPA and ATRA treatments confer distinct phenotypic signatures on Tregs 
Human Treg cells have been shown to be a heterogeneous population in the expression 
of cell surface markers. In order to investigate if RAPA, ATRA and the combination of both 
drugs were effective in promoting phenotypic signatures on these cells, the surface expression 
of several molecules expressed by Treg cells after 28 days of culture was evaluated. Flow 
cytometric analysis in Figure 4A shows that all Treg preparations maintained low levels of 
CD127 whose expression has been reported to be inversely correlated with human Treg 
suppressive function in vitro. Another surface marker that appears promising to identify Treg 
cells is CD62L. CD62L (L-selectin) is a member of the selectin adhesion molecule family and 
is required for lymphocyte homing to peripheral lymph nodes (Butcher and Picker, 1996). 
Transcriptional loss of CD62L is frequently used as a marker to distinguish naïve and antigen 
experienced T cells in the blood and lymphoid organs during immune responses (Bradley et 
al., 1991). The application of this paradigm to Treg cells is problematic as very little is known 
about antigen experience of these cells. However, recent data showed that Treg CD62L+ cells 
possess superior regulatory activity in vivo (Ermann et al., 2005). Therefore, it has been 
analyzed whether the percentage of Treg cells expressing this molecule differed between our 
Treg preparations. It has been found a high percentage of Treg cells expressing CD62L in 
RAPA- and RAPA plus ATRA-treated Treg cells in comparison with untreated or ATRA-
treated Treg cells. Interestingly in the same Treg culture conditions, RAPA- and RAPA plus 
ATRA-treated Treg cells, a high percentage of cells expressing CD27 was observed. This 
molecule is a member of the TNF-receptor superfamily and it has been shown to be correlated 
with regulatory activity in Treg cells expanded from CD4+CD25+ T cells (Duggleby et al., 
2007). Like CD62, is CD27 is present on both naïve CD4+CD25- T cells and Treg cells before 
activation. However this molecule is down-regulated in conventional T cells after activation 
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while it is maintained in a very suppressive Treg cell subset. Flow cytometric analysis in 
Figure 4B confirms previous data showing high percentages of Treg cells co-expressing 
CD62L and CD27 molecules in RAPA- and RAPA plus ATRA-treated Treg preparations. 
Lower expression of the same markers were expressed in both untreated and ATRA-treated 
cells. To notice, the co-expression of these two molecules by Treg cells has been associated 
with high suppressive ability both in vitro and in vivo (Issa et al., 2010; Koenen et al., 2008; 
Koenen et al., 2005; Nadig et al., 2010 ). Based on this evidence, these results suggest that 
either RAPA alone or RAPA in combination with ATRA could selectively induce the 
expression of markers involved in Treg activity.  
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Figure 4.  
 
 
 
Fig. 4. Phenotypic analysis of untreated, RAPA-, ATRA- or RAPA+ATRA-treated Treg 
cells. (A) Percentage of expression of indicate molecules was calculated after 28 days of Treg 
cell   culture. Bar graphs show mean ± s.d. of 7 independent experiments. Asterisks indicate 
significant differences compared to untreated cells and between different Treg drug treatment 
*p<0.05, **p<0.01, ***p<0.001. (B) Flow cytometry analysis of CD27 and CD62L co-
expression on differently treated Treg cell lines is shown. Dot plots depicted are from 7 
independent experiments  
 
A 
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3.4.5. RAPA and ATRA augment the expression of homing receptors on Treg cells 
Migration of Treg cells to secondary lymphoid organs is critical for limiting activation 
of immune cells in response to alloantigens and is important for hematopoiesis and prevention 
of GVHD after allogenic transplantation. Human Treg cells have been shown to express a set 
of homing receptors for their trafficking from the blood circulation to peripheral tissues and 
for their subsequent migration to draining lymph nodes (Kim, 2006). Therefore, It has been 
investigated whether the expression of different homing receptors of Treg cells could be 
affected by drug treatments. After 28 days of culture, CLA, CCR4, CCR9 and integrin α4β7 
expression in Treg preparations was analyzed by flow cytometry. The expression of CLA and 
CCR4 is important for skin homing while CCR9 and integrin α4β7 are related to the liver and 
gut homing trafficking. As shown in Figure 5 a high percentage of Treg cells co-expressing 
CLA and CCR4 in RAPA treated Treg cells was observed, whereas ATRA-treatment resulted 
in high percentages of cells co-expressing liver and gut homing receptors CCR9 and integrin 
α4β7. Finally, Treg cells treated with both drugs showed the combined homing characteristic 
features of Treg cells stimulated by each drug. These results highlight that the treatments with 
RAPA and ATRA could preferentially induce the expression of different homing receptors. As 
migration receptors on Treg cells are highly informative in assessing Treg behavior in vivo, 
this  evidence has important relevance for the use of these two drugs in the treatment of 
diseases with very well defined target organs. 
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Figure 5.   
                                                   
Fig. 5. Expression of homing receptors on Treg cell lines. Untreated, RAPA-, ATRA- or 
RAPA+ATRA-treated Treg cells at day 28 of culture were analyzed by flow cytometry for the 
expression of the reported molecules. Data are expressed as percentage of positive cells for 
each molecule. Bar graph depicts the  mean ± s.d of 7 independent experiments. Asterisks 
indicate significant differences compared to untreated cells and between different Treg drug 
treatment *p<0.05, **p<0.01, ***p<0.001. 
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3.4.6. Treg cells expanded in the presence of RAPA, but not ATRA, do not produce 
inflammatory cytokines 
Treg cells were initially believed to be highly specialized and fully committed to 
suppress effector T cells proliferation at all times. However, their lineage programs exhibit 
unexpected plasticity. They can lose FOXP3 expression with a resultant loss of 
immunosuppressive function and acquisition of a pro-inflammatory phenotype (Hori, 2010). 
Treg cells are potential immunotherapeutic tools and the capacity to produce pathogenic 
cytokines in an inflammatory environment is an undesirable option. In order to evaluate the 
stability of bead-purified Treg cells expanded in the different conditions described above, the 
production of two inflammatory cytokines, IL-17 and IFN-γ, following RAPA- and/or ATRA-
treatment was measured. Supernatants from 28 day cell culture were analysed for the presence 
of IL-17 and IFN-γ by ELISA. Data showed that ATRA-treated Treg cells produced levels of 
IL-17 and IFN-γ comparable to untreated Treg cells (Figure 6A). In contrast, Treg cultures 
expanded with RAPA or RAPA plus ATRA showed a strong decrease of these cytokines. This 
result suggests that the presence of RAPA may help to preserve the stability of ex vivo 
expanded Treg cells in order to assure safety when they are re-stimulated with alloantigen 
even in an inflammatory milieu. To investigate this possibility, we measured IL-17 production 
from our Treg preparations cultured in the presence of pro-inflammatory cytokines that favour 
the skewing to inflammatory Th17 lineage. In this regard, two different cytokine cocktails, 
cocktail A (IL-1β, IL-2, IL-6 and TGF- β) and cocktail B (IL-2, IL-21, IL-23 and TGF- β), 
reported to induce Th17 conversion, have been used. The analysis of supernatants after 7 days 
of culture in the absence of treatments showed significant increase of IL-17 production in 
supernatants of freshly isolated Treg cells, untreated and ATRA-treated Treg cells in the 
presence of both cocktails (Figure 6B). On the contary, no IL-17 secretion in RAPA– and 
RAPA plus ATRA-treated Treg supernatants in response to the cocktails was detected (Figure 
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6B, bottom left and bottom right), ATRA-treatment in combination with pro-inflammatory 
cytokines and in particular of cocktail B, significantly increased the production of IL-17 by 
Treg cells (Figure 6B, bottom middle). This result confirms the previous findings empathizing 
the role of RAPA or the combination RAPA plus ATRA to ensure in vitro the stability of Treg 
cells even in an inflammatory context. These data also  confirm that ATRA-treatment fails to 
protect Treg cells against Th17 conversion favoring IL-17 production by Treg cell 
preparations. 
Figure 6. 
 
 
A 
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Fig. 6. Effect of RAPA, ATRA or RAPA+ATRA on cytokine production by Treg cell lines. 
(A) Treg cells were stimulated with anti-CD3/CD28 beads and IL-2 (1000 IU/mL) in the 
presence or absence of drugs and cultured for 28 days. Supernatants of Treg preparations were 
collected after 7 days of culture in the absence of drugs.IL-17 and IFN-γ production was 
measured by ELISA. Bar graphs show the cumulative mean ± s.d. from 5 independent 
experiments. (B) Treg stability in the presence of pro-inflammatory milieu was valuated 
measuring IL-17 concentration in fresh CD4+CD25+ T cell and Treg cell culture supernatants. 
IL-17 concentration was measured after 1 week of culture in the absence of drugs and in the 
presence of only IL-2 (10 IU/ml) or 2 different cytokines cocktails. Cocktail A (CA): IL-2, IL-
1β, IL-6, TGF- β. Cocktail B (CB): IL-2, IL-21, IL-23, TGF- β. Graphs show pooled mean ± 
s.d. from 3 independent experiments Asterisks indicate significant differences in cytokine 
production compared to untreated cells and between different Treg drug treatment. *p<0.05, 
**p<0.01, ***p<0.001. 
 
3.4.7. ATRA-treatment promotes FOXP3+CD161+ Treg expansion in vitro 
To better characterize the nature of IL-17-producing Treg cells, the expression of 
CD161 was analyzed. This molecule has been found to be correlated with the ability of T cells 
to produce IL-17, and it has been described as a marker for Th17 cells (Cosmi et al., 2008; 
Maggi et al., 2010). CD161 interacts with CLEC2A, a molecule that belongs to the C-type 
lectin domain family 2 (CLEC) (Rosen et al., 2005). CLEC2A is selectively expressed in the 
skin where Th17 cells migrate in the course of chronic inflammatory disorders (Spreu et al., 
2007). Thus, CD161 expression could allow the trans-endothelial migration of Th17 cells into 
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tissues. Treg cell lines were cultured as previously described in the presence of absence of 
RAPA (100 nM), RAPA plus ATRA (100 nM and 2 μM respectively) and different 
concentrations of ATRA alone. As illustrated in Figure 7, the percentage of CD161-
expressing Treg cells cultured with increasing concentrations of ATRA was higher in 
comparison with untreated Treg cells. On the contrary, in RAPA-treated Treg cells the 
proliferation of this subset was significantly suppressed. The difference in CD161 expression 
between RAPA and ATRA-treated Treg cells, reached statistical significance when ATRA was 
used at the highest concentration (2μM). Surprising, in the presence of both drugs, the 
percentage of CD161+ Tregs was similar to that found in cultures treated with ATRA alone. 
Thus, the combination of ATRA and RAPA in Treg preparations showed that the addition of 
both ATRA and RAPA has an additive effect inhibiting IL-17 production and favouring 
CD161 expression. The latter evidence also suggests that IL-17 release and CD161 expression 
are controlled by two molecular pathways differently affected by RAPA.  
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Figure 7. 
 
Fig. 7. Percentage of CD161-expressing Treg cells cultured with increasing 
concentrations of ATRA. The percentage of expression CD161 molecule was valuated on 
Treg cell preparations by flow analysis. Treg cell lines were cultured  with RAPA (100 nM) 
RAPA+ATRA (100 nM and 2 μM respectively) or with different concentrations of ATRA. Bar 
graph shows cumulative mean ± s.d. from 3 independent experiments. Asterisks indicate 
significant differences in CD161 expression compared to untreated cells and between 
different Treg drug treatments. **p<0.01, ***p<0.001 
 
 
 3.4.8. RAPA-treatment favors selectively naive Treg subset expansion in vitro 
All the data presented so far have been obtained with bead-separated Treg cells 
expanded under different conditions. Human FOXP3+ Treg cells are phenotypically and 
functionally heterogeneous including suppressive and non-suppressive T cells. The 
subpopulations described by Miyara et al, resting FOXP3low CD45RA+ Treg cells (P1, nTreg 
cells), effector or activated FOXP3hi CD45RA- Treg cells (P2, eTreg cells) and cytokine-
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secreting FOXP3lowCD45RA- non suppressive Treg cells (P3, non Treg cells), have been 
shown to behave differently in vitro and in vivo upon activation (Miyara et al., 2009). Based 
on this evidence, the effect of RAPA, ATRA or the combination of both drugs on 
proliferation of these subpopulations was tested. CD4+ T cells were enriched from human 
PBMC as described in Materials and Methods and then sorted according their levels of CD25 
and CD45RA (Figure 8A). Treg subset proliferation was monitored for 28 days of culture in 
the presence or absence of drugs. P2 did not expand at all within any of the in vitro culture 
conditions (data not shown), while P1 and P3 proliferated in the presence of the different drug 
treatments (Figure 8B-C). It has been observed also that during the first week of culture P3 
subset grew more slowly both in the presence and in absence of dugs than P1 subset expanded 
under the same drug treatments (Figure 8C). After the first re-stimulation (R1) P1 and P2 
Treg proliferation was comparable in all the culture conditions and reached a peak around the 
third re-stimulation (R3). The graphs suggest also that while ATRA-treatment tended to 
promote P3 expansion without affecting P1 subset, RAPA seemed to favor P1 proliferation.  
To better investigate the influence of the drugs on the two Treg subsets, P1 and P3 population 
doubling after the first re-stimulation (R1) was evaluated. As depicted in Figure 8D, cell-
sorted Treg subsets showed expansion rates comparable to the “whole” Treg cells described 
above in the section 3.4.2. Interestingly, this result confirms the suspicion showing that while 
P1 Treg expansion was affected by the presence of RAPA, ATRA alone enhanced only P3 
subset proliferation. In culture containing both the drugs, the proliferative effect of ATRA on 
P3 subset was overcome by RAPA resulting in a selective P1 Treg expansion. As P1 Treg 
cells have been described as the most stable of the subpopulations, this evidence suggests that 
the effect mediated by RAPA to enhance the expansion of a specific Treg subset rather than 
whole FOXP3+ T cells, may be a promising strategy for the management of various 
immunological diseases.  
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Fig. 8. Treg subsets expansion in the presence of different treatment. (A) Gating strategy 
for Treg subsets cell sorting is shown. CD4+ T cells were isolated for human PBMCs prior to 
sorting on a BD FACSAria. (B-C) P1 (B) and P3 (C) cell count was performed at weekly 
intervals (R) throughout 4 rounds of stimulation. Cumulative data from 5 different P1 and P3 
Treg subpopulations are shown. (D) Bar graphs depict the in vitro expansion of RAPA-, 
ATRA- or RAPA+ATRA- treated P1 and P3 Treg lines after the first round of stimulation 
(R1). Cumulative data from 5 different P1 (B) and P3 (C) Treg lines are expressed as 
population doubling. Asterisks indicate significant differences compared to untreated cells and 
between P1 and P3 Treg subseets. *p<0.05, **p<0.01. 
 
3.4.9. Only RAPA protects Treg subsets from pro-inflammatory cytokines production 
 The next step was to understand whether the inhibitory effect of RAPA on pro-
inflammatory cytokines production observed in “whole” RAPA- treated Treg culture, was due 
to a selective effect of the drug on P1 subset. To this aim, an ELISA was performed to 
measure IL-17 and IFN-γ production in P1 and P3 subpopulations following RAPA- and/or 
ATRA-treatment. Supernatants of P1 and P3 subset were collected after 4 rounds of 
stimulation and IL-17 and IFN-γ production was measured by ELISA. Cytokine analysis 
revealed that while P1 did not produce IL-17 in any of the culture conditions (Figure 9A), 
untreated and ATRA Treg cells derived from P3 subset produced large amounts of IL-17. The 
same analysis showed that the production of this cytokine was inhibited only by the addition 
of RAPA both in P1and P3 cultures. No significant differences among the other culture 
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conditions of P3 for IFN- γ production were observed. (Figure 9B). Although not statistically 
significant, P1 Treg cells showed some IFN-γ production particularly following treatment 
with ATRA. These findings were further confirmed looking at IL-17 and IFN-γ production on 
a per cell basis by intracellular staining. Both subpopulations, cultured in the presence or in 
the absence of drugs, were stimulated and stained for intracellular IL-17 and IFN-γ cytokines 
as described in Material and Methods. A higher percentage of IFN-γ / IL-17+ P3 Treg cells in 
ATRA preparations in comparison to the other culture conditions was observed (Figure 9C). 
On the contrary, no IL-17+ P1 Treg cells were found in the cultures containing ATRA 
although this drug increased the percentage of IFN-γ P1 Treg cells. However, both the 
percentage of P1 and P3 Treg cells expressing IL-17 and IFN-γ was reduced by RAPA as 
observed above with regard to the absolute concentrations of the two cytokines in ELISA. 
These results suggest that ATRA as single agent, in comparison to RAPA, is unable to 
promote the generation of a stable Treg subpopulation. Based on this evidence, only RAPA or 
the combination of both drugs could be a potential avenue to prevent pro-inflammatory 
cytokines production. Since the  presence of ATRA alone favoured IL-17 production by 
“whole” Treg cells and in particular by P3 subset, in according to the same assumption 
previously described, CD161 expression in subset preparations was investigated,. As depicted 
in Fig 6D, the cytokine profile of both P1 and P3 correlated very well with the expression of 
this marker. In all the culture conditions, P3 subset contained the highest percentage of cells 
expressing CD161 molecule, which was decreased when P3 was cultured with RAPA. In 
contrast, P1 subpopulation showed a lower number of cells expressing CD161 and again 
RAPA was able to further decrease it. Together, these data confirms that P1 subset is more 
stable than P3 subset in vitro emphasizing the pivotal role of RAPA in this process. 
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Figure 9. 
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Fig. 9. Treg subsets stability and CD161 expression in the presence of different 
treatment. (A-B) Comparison of IL-17 (A) and IFN-  (B) production by ELISA in 7 days 
supernatants of P1 and P3 Treg lines. (C) The percentage of IL-17+ and IFN-   cells in 
CD25+FOXP3+ P1 and 3 cultured with different treatments was measured by intracellular 
staining. (D) Bar graph shows a   comparison of CD161 expression in P1 and P3 Treg lines. 
All data are from Treg cell lines after 4 rounds of stimulation. Dot Plots are representative of 
5 independent experiments. Asterisks indicate significant differences compared to untreated 
cells and between P1 and P3 Treg subseets. *p<0.05, **p<0.01. 
 
3.4.10. The more stable P1 phenotype results in a potent suppressive activity in vitro 
Given that P1 Treg cells have been shown to be in vitro more suppressive than P3 
subset (Miyara et al., 2009), the function of each Treg subset after drug-conditioning was 
tested. To this aim, a suppression assay as previously described for in vitro expanded “whole” 
Treg cells was performed. P1 consistently showed a tendency to have superior suppressive 
abilities independent of the culture treatment, compared to P3. Interestingly, statistically 
significant differences in the suppressive function of these subsets were observed when P1 
cultures were treated with ATRA alone. (Figure 10). Thus, this result confirms the inherent 
differences of suppressive activity between P1 and P3 subpopulations reported in the 
literature. Moreover, as in the presence of ATRA the function of P1 subset was significantly 
higher, one could suppose that this drug exerts a positive effect on expanded P1 Treg 
function.  
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Figure 10. 
 
Fig. 10. Treg subsets suppressive abilities in the presence of different treatments. A 
comparison of P1 and P3 suppressive abilities at different ratios of Treg:Teff after 4 rounds of 
stimulation in the presence or absence of drugs. from 5 independent experiments Data from 5 
independent experiments are expressed as average percent of suppression of proliferation of 
Teff cells alone. Statistical analysis shown only on significantly different data. **p<0.01. 
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3.5. Discussion  
Of  particular interest is the potential for the CD4+CD25+FOXP3+ Treg cells to be used 
as a cellular therapy in the context of organ transplantation for the induction of tolerance 
(Lombardi et al., 2011). However, the small number of  CD4+CD25+FOXP3+ Treg cells 
accessible in the peripheral circulation means that for cellular therapy is necessary to expand 
clinically sufficient numbers of Tregs in vitro. So, the second part of my PhD project was to 
optimize a Treg expansion protocol to maintain a pure, suppressive, and stable Treg 
population, with well defined Treg homing characteristics for in vivo Treg targeting to specific 
sites. So far much work has gone into developing in vitro methods to expand Treg cells. 
Methods employed to stimulate CD4+CD25+FOXP3+ Treg cells include anti-CD3/anti-CD28 
coated beads as well as cell-based artificial antigen presenting cells expressing co-stimulation 
molecules and/or Fc receptors. In addition to stimulus through TCR and CD28 co-stimulation, 
Treg cells require also exogenous IL-2. Adding Rapamycin to the culture has been shown to 
preserve Treg purity and allow selective Treg expansion. Indeed RAPA gives a proliferative 
advantage to Tregs by affecting basic signal pathways such as Akt/mTor, which is not 
essential for Tregs (Peter et al., 2010). Notably, rapamycin- expanded Treg cells retain 
suppressive capacity in vitro and, when tested in a GVHD model, were more effective than 
natural Tregs expanded under conventional conditions. Other studies have shown that ATRA 
is also a suitable treatment for the induction of adaptive Tregs (Mucida et al., 2009). Indeed, 
recently ATRA has been described as a treatment to expand human nTregs (Golovina et al., 
2011). The molecular pathway by which ATRA favors the expansion of Tregs is not 
completely clear, but it is thought to induce chromatin decondensation recruiting histone 
acetyltransferases and transcription machinery to the FOXP3 promoter (Kang et al., 2007; 
McGrane et al., 2007). However, due to its multi-faceted effects on gene transcription, ATRA 
has also been shown to affect T cell fate by contributing to Th1/Th17 differentiation (Hall et 
 122 
al., 2011). In this thesis it has also identified significant differences between untreated, 
RAPA- and ATRA-treated Tregs in terms of homing receptor expression. Although others 
have previously reported that Tregs express multiple homing receptors (Hirahara et al., 2006; 
Zhang et al., 2009), such as CD62L (Hoffmann et al., 2006; Baecher-Allan et al., 2001, 
Iellem et al., 2003), CCR4 (Hirahara et al., 2006; Iellem et al., 2003, Lee et al., 2005), CLA 
(Hirahara et al., 2006; Iellem et al., 2003, Booth et al., 2010) and CCR7 (Iellem et al., 2003, 
Hoffmann et al., 2004), this is the first study in which the expression of homing receptors was 
evaluated on human Tregs during ex vivo expansion with drug conditioning. The migration of 
these Treg preparations in vivo is now under investigation. The major concerns in Treg 
therapy is to prevent the induction and expansion of IL-17-producing cells, which could arise 
from Teffs contaminating the Treg preparations (Cosmi et al., 2010), and/or FOXP3+ Tregs 
converting to IL-17-producing cells (Koenen et al, 2008). The reported data clearly show that 
RAPA has an inhibitory effect on the development of IL-17-producing cells, both in vitro and 
in vivo. This is consistent with previous descriptions in the literature of the inhibitory effect of 
RAPA on Th17 cells (Tresoldi et al., 2011). In contrast, the data of this thesis show that ATRA 
maintained the expansion of IL-17 and IFN-γ producing FOXP3+ Tregs. The effect of ATRA 
on Th17 cells has been controversial. Some in vitro studies have shown that retinoic acid 
induces pro-inflammatory T cell responses while others demonstrated that ATRA strongly 
inhibits Th17 polarization in vitro (Mucida et al., 2007; Elias et al., 2008;  Hippen et al., 
2011). Furthermore Hall and collaborators have demonstrated in vivo that in mice fed with a 
vitamin A deficient diet, robust Th17 and Th1 responses are generated (Hall et al., 2011). The 
general conclusion is that the effect of retinoic acid is very much dependent upon its 
concentration and the inflammatory environment in which the immune response takes place 
(Wang et al., 2009; Hall et al., 2011; Uematsu et al., 2008). This study has demonstrated that 
ATRA expanded Treg highly suppressive phenotype, but at the same time did not prevent IL-
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17 secretion. Notably, isolation of CD25+CD45RA+ (naïve) T cells (P1) yields Treg cells with 
a grater suppressive capacity than total CD4+CD25+FOXP3+ Treg cells. The reason of this 
became clear when Miyara et al. examined subpopulation of human FOXP3+ T cells and 
discovered that the CD25+CD45RA-FOXP3low T (P3) population is not suppressive in vitro, 
contains IFN-γ and IL-2 producing cells, and also could contain Th17 precursors (Miyara et 
al., 2009). After three weeks of in vitro expansion, CD127- Treg cells became methylated at 
the TSDR while CD45RA+ expanded Treg cells remained de- methylated. Moreover, the 
CD127- Treg cells that lost FOXP3 expression were CD45RA- suggesting that naïve Treg cells 
may represent the most stable population for expansion. So this result obtained with drug 
conditioning of “whole” Tregs was tested on Treg cell subsets sorted and cultured with RAPA 
and/or ATRA. It has demonstrated that the presence of RAPA provided an initial proliferative 
advantage to P1, while the same drug had an inhibitory effect on the P3 subset. In contrast, 
ATRA conditioning favored expansion of cells in P3. This finding leads to the hypothesis that 
when the two drugs were used with “whole” Tregs, RAPA expands P1 to the detriment of P3, 
while ATRA allows the expansion of cells within the P3 that retain IL-17 secretion capacity. It 
is noteworthy that analysis of CD161 in general confirms this hypothesis by showing a higher 
percentage of Tregs expressing this marker in P3. However when P3 is cultured with the 
combination of RAPA and ATRA, the same percentage of Tregs expressed CD161 while IL-
17 production was reduced, suggesting that these two parameters do not necessarily correlate. 
In addition it is also not clear why the percentage of Tregs expressing CD161 molecule 
increased when ”whole” Treg are treated with ATRA but not when the single subpopulations 
are treated with the same drug. This result may be explained by the influence of the two 
subpopulations on each other when “whole” Tregs are treated with ATRA and needs further 
investigation. In conclusion, this study has identified a clinically applicable protocol to obtain 
and expand human immunomagnetic bead-separated CD4+CD25+ Tregs. These additional 
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data performed in vitro describe how the treatment with RAPA and ATRA can affect Treg 
phenotype, function and plasticity during cell expansion. Moreover it has been demonstrated 
directly for the first time that one of the ways that RAPA stabilizes Tregs is by selecting and 
expanding the subpopulation of functional, no plastic naive Tregs (Miyara et al., 2009; 
Hoffmann et al., 2006). In contrast, the effect due to ATRA can be explained by the fact that 
this drug favors the expansion of P3 that contains cells that retain the capacity to produce IL-
17. Although these findings further emphasize that Treg therapy with bead-separated Tregs 
requires RAPA for the expansion of functional and stable Tregs, the selection of additional 
drug, such as ATRA, can be based on the type of organ or tissue targeted. So, the Treg 
expansion protocol here reported suggests that the combination of ATRA and RAPA may be 
an ideal culture condition to expand Tregs for their use in the induction of tolerance.  
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4. General Conclusion  
The sine qua non for Treg stability and function is the sustained expression of the 
transcription factor FOXP3. Here FOXP3 plays a key role in tolerance by mediating the 
ability of Treg cells to suppress immune responses including controlling autoreactive T cells 
circulating in the periphery and limiting responses to the infections. Unfortunately, we do not 
know yet how exactly Treg cells suppress immune responses, though several mechanisms 
have been proposed, and we understand even less about how FOXP3 might orchestrate these 
mechanisms. So, a better knowledge of FOXP3 activity in Treg cells would be extremely 
useful either to boost or inhibit their function for maintaining immune homeostasis. Of 
particular interest is the potential for CD4+CD25+ FOXP3+ Treg cells to be used as  cellular 
therapy in preventing graft rejection and inducing tolerance. Compelling evidence from 
animal models demonstrated the efficacy of Treg therapy proividing a strong framework for 
testing Treg therapy in humans. However, the low frequency of Treg cells accessible in the 
peripheral circulation led to the need to expand ex vivo these cells. Therefore, the two 
researchs presented here aimed both to investigate the molecular mechanisms by which 
FOXP3 activates gene transcription and to optimize a protocol that can reliably produce large 
numbers of clinical grade, highly pure and stable suppressive CD4+CD25+ FOXP3+ Treg 
cells. Together these studies contribute to the large body of literature that demonstrates the 
importance of FOXP3 in immune cell function and the prospect of using Treg cells as therapy 
in various transplant models. Although much work is still to be done in this regard, there is 
now ample evidence to support the translation of this approach to the clinical arena. 
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